Patient-Reported Outcomes after Monitoring, Surgery, Cancer

New England Journal of Medicine 375, 1425-1437 DOI: 10.1056/nejmoa1606221

Citation Report

#	Article	IF	CITATIONS
1	Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?. BioMed Research International, 2016, 2016, 1-14.	1.9	44
2	Urinary quality of life outcomes in men who were treated with image-guided intensity-modulated radiation therapy for prostate cancer. Advances in Radiation Oncology, 2016, 1, 310-316.	1.2	2
5	The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?. BJU International, 2016, 118, 843-843.	2.5	5
6	Treatment or Monitoring for Early Prostate Cancer. New England Journal of Medicine, 2016, 375, 1482-1483.	27.0	15
7	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 2016, 375, 1415-1424.	27.0	2,101
8	Who Should Consider Active Surveillance?. Journal of Urology, 2016, 196, 1604-1605.	0.4	0
9	Patients with Differentiated Thyroid Cancers 1 to 2 cm Are Treated Differently from Those With Tumors Smaller than 1 cm. Clinical Thyroidology, 2016, 28, 296-298.	0.1	0
10	Determining optimal therapy of early-stage disease remains complicated. Nature Reviews Urology, 2016, 13, 703-704.	3.8	0
11	Trends in Radiation Therapy among Cancer Survivors in the United States, 2000–2030. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 963-970.	2.5	93
14	Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. Health Affairs, 2017, 36, 108-115.	5.2	25
15	10-Year Outcomes in Localized Prostate Cancer. New England Journal of Medicine, 2017, 376, 178-181.	27.0	16
16	Reply to: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. Hamdy et al. NEJM October 2016. World Journal of Urology, 2017, 35, 1465-1465.	2.2	0
17	Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer. Quality of Life Research, 2017, 26, 1635-1645.	3.1	24
18	Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. European Urology, 2017, 72, 617-624.	1.9	50
19	Active Surveillance Versus Treatment of Prostate Cancer: Should Metastasis Be the Primary End Point?. Journal of Clinical Oncology, 2017, 35, 1638-1640.	1.6	12
20	Prostate cancer screening practices in a large, integrated health system: 2007–2014. BJU International, 2017, 120, 257-264.	2.5	29
21	Long Term Patient Reported Urinary Function Following External Beam Radiotherapy for Prostate Cancer. Clinical Oncology, 2017, 29, 421-428.	1.4	7
22	Does early resection of presumed low-grade glioma improve survival? A clinical perspective. Journal of Neuro-Oncology, 2017, 133, 137-146.	2.9	35

#	Article	IF	CITATIONS
23	Partial Gland Treatment of Prostate Cancer Using High-Intensity Focused Ultrasound in the Primary and Salvage Settings: A Systematic Review. Journal of Urology, 2017, 198, 1000-1009.	0.4	38
24	Late Genitourinary Toxicity Outcomes in 300 Prostate Cancer Patients Treated With Dose-escalated Image-guided Intensity-modulated Radiotherapy. Clinical Oncology, 2017, 29, 617-625.	1.4	13
25	Patient Knowledge and Qualities of Treatment Decisions for Localized Prostate Cancer. Journal of the American Board of Family Medicine, 2017, 30, 288-297.	1.5	15
26	A Pragmatic Randomized Controlled Trial Examining the Impact of the Retzius-sparing Approach on Early Urinary Continence Recovery After Robot-assisted Radical Prostatectomy. European Urology, 2017, 72, 677-685.	1.9	154
27	Comparative effectiveness of prostate cancer treatments for patient-centered outcomes. Medicine (United States), 2017, 96, e6790.	1.0	18
29	The <i><scp>BJUI</scp></i> 's clinical trials initiative. BJU International, 2017, 119, 503-503.	2.5	0
30	Prostate Cancer and the John West Effect. European Urology, 2017, 72, 7-9.	1.9	6
31	Overactive bladder syndrome and lower urinary tract symptoms after prostate cancer treatment. Current Opinion in Urology, 2017, 27, 307-313.	1.8	16
32	Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?. Prostate Cancer and Prostatic Diseases, 2017, 20, 323-327.	3.9	16
33	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. Clinical Genitourinary Cancer, 2017, 15, e801-e807.	1.9	16
35	Healthâ€related quality of life in prostate cancer patients'–Âtreatment comparisons. International Journal of Urological Nursing, 2017, 11, 98-105.	0.2	0
36	Longâ€term quality of life after definitive treatment for prostate cancer: patientâ€reported outcomes in the second posttreatment decade. Cancer Medicine, 2017, 6, 1827-1836.	2.8	25
37	Toxicity after postâ€prostatectomy imageâ€guided intensityâ€modulated radiotherapy using Australian guidelines. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 804-811.	1.8	2
38	You Pays Your Money, You Takes Your Choice: Functional Outcomes Following Curative Treatment for Clinically Localized Prostate Cancer. Urology, 2017, 107, 3-4.	1.0	0
39	New advances in focal therapy for early stage prostate cancer. Expert Review of Anticancer Therapy, 2017, 17, 737-743.	2.4	16
40	MRI pathway and TRUS-guided biopsy for detecting clinically significant prostate cancer. The Cochrane Library, 2017, , .	2.8	2
41	Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary. Current Urology Reports, 2017, 18, 53.	2.2	7
42	Understanding and Improving Recruitment to Randomised Controlled Trials: Qualitative Research Approaches. European Urology, 2017, 72, 789-798.	1.9	105

#	Article	IF	CITATIONS
43	The clinical communication and information challenges associated with the psychosexual aspects of prostate cancer treatment. Social Science and Medicine, 2017, 185, 17-26.	3.8	25
44	When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers. Cancer Treatment Reviews, 2017, 58, 14-21.	7.7	12
45	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. Journal of Urology, 2017, 198, 1061-1068.	0.4	31
46	Prevention of Prostate Cancer Morbidity and Mortality. Medical Clinics of North America, 2017, 101, 787-806.	2.5	115
47	Patient-reported outcome measures in urology. Current Opinion in Urology, 2017, 27, 366-374.	1.8	29
48	The Artificial Urinary Sphincter: Evolution and Implementation of New Techniques in the Man with Stress Incontinence After Treatment for Prostate Cancer. Current Bladder Dysfunction Reports, 2017, 12, 159-166.	0.5	0
49	Comparing quality of life outcomes after prostate cancer treatment. Nature Reviews Urology, 2017, 14, 396-397.	3.8	1
50	Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1053-1058.	0.8	6
51	Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1141.	7.4	250
52	Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1121.	7.4	15
53	Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA - Journal of the American Medical Association, 2017, 317, 1126.	7.4	261
54	Patient-reported outcomes in cancer survivorship. Acta OncolÃ ³ gica, 2017, 56, 166-173.	1.8	39
55	To ProtecT Our Patients With Prostate Cancer. JAMA Oncology, 2017, 3, 1461.	7.1	2
56	Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017, 72, 238-249.	1.9	55
57	Clinically localized prostate cancer in 2017: A review of comparative effectiveness. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 40-41.	1.6	20
58	Predictors of multidomain decline in healthâ€related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer, 2017, 123, 1635-1642.	4.1	14
59	†ProtecTion' from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer?. BJU International, 2017, 119, 513-514.	2.5	5
60	A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. International Iournal of Radiation Oncology Biology Physics. 2017. 97. 962-975.	0.8	45

#	Article	IF	CITATIONS
61	Contemporary Active Surveillance. Urologic Clinics of North America, 2017, 44, 565-574.	1.8	20
62	ProtecTing Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 515-517.	0.8	3
63	Editorial Comment. Urology, 2017, 109, 151-152.	1.0	1
64	Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. Urology, 2017, 109, 145-152.	1.0	4
65	In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance. Evidence-Based Medicine, 2017, 22, 192-192.	0.6	1
66	A House Divided: The Irradiation Versus Prostatectomy Debate Continues. International Journal of Radiation Oncology Biology Physics, 2017, 99, 512-514.	0.8	3
68	Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. European Urology Focus, 2017, 3, 615-620.	3.1	44
69	The Natural History of Erectile Dysfunction After Prostatic Radiotherapy: A Systematic Review and Meta-Analysis. Journal of Sexual Medicine, 2017, 14, 1071-1078.	0.6	50
70	Prevalence and associations of general practitioners' ordering of "non-symptomatic― prostate-specific antigen tests: A cross-sectional analysis. International Journal of Clinical Practice, 2017, 71, e12998.	1.7	3
71	Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES. International Urology and Nephrology, 2017, 49, 1715-1721.	1.4	17
72	Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years. Journal of Urology, 2017, 198, 466-468.	0.4	0
73	Current trends in patient enrollment for roboticâ€assisted laparoscopic prostatectomy in Belgium. Cancer, 2017, 123, 4139-4146.	4.1	8
74	Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. International Journal of Urology, 2017, 24, 743-748.	1.0	34
75	Surgical Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical Prostatectomy for Prostate Cancer. Current Urology Reports, 2017, 18, 71.	2.2	54
76	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. European Urology, 2017, 72, 869-885.	1.9	182
77	Voiding Dysfunction, Incontinence, and Erectile Dysfunction Following High-Intensity Focus Ultrasound and Focal Cryotherapy in Treatment of Prostate Cancer. Current Bladder Dysfunction Reports, 2017, 12, 285-290.	0.5	1
78	Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 664.e1-664.e9.	1.6	73
79	Prostatectomy versus radiotherapy for early-stage prostate cancer (PREPaRE) study: protocol for a mixed-methods study of treatment decision-making in men with localised prostate cancer. BMJ Open, 2017, 7, e018403.	1.9	3

#	Article	IF	CITATIONS
80	Reporting Erectile Function Outcomes After Radiation Therapy for Prostate Cancer: Challenges in Data Interpretation. Journal of Sexual Medicine, 2017, 14, 1260-1269.	0.6	13
81	The Diagnosis and Treatment of Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2532.	7.4	959
84	Lessons Learned from Two Decades of Anticancer Drugs. Trends in Pharmacological Sciences, 2017, 38, 852-872.	8.7	74
85	Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. New England Journal of Medicine, 2017, 377, 132-142.	27.0	460
88	Focal Therapy for Prostate Cancer with In-Bore MR–guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial—Complications and Functional Outcomes. Radiology, 2017, 285, 620-628.	7.3	40
89	The evolution of brachytherapy for prostate cancer. Nature Reviews Urology, 2017, 14, 415-439.	3.8	106
90	Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. Abdominal Radiology, 2017, 42, 918-925.	2.1	26
91	Je le pansai, Dieu le guerit. European Urology, 2017, 72, 343-344.	1.9	5
92	Screening and treatment: where do we go from here?. Nature Reviews Clinical Oncology, 2017, 14, 7-8.	27.6	1
93	The Surgical Management of Prostate Cancer. Seminars in Oncology, 2017, 44, 347-357.	2.2	60
94	Categorising cancers to enable tailored care planning through a secondary analysis of cancer registration data in the UK. BMJ Open, 2017, 7, e016797.	1.9	14
95	In patients with localised prostate cancer, active surveillance is associated with better sexual function, urinary symptoms and bowel symptoms. Evidence-Based Medicine, 2017, 22, 217-218.	0.6	0
97	Neuroprotective and Nerve Regenerative Approaches for Treatment of Erectile Dysfunction after Cavernous Nerve Injury. International Journal of Molecular Sciences, 2017, 18, 1794.	4.1	35
98	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	2.8	36
99	Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer. Frontiers in Oncology, 2017, 7, 227.	2.8	5
100	Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population. Canadian Urological Association Journal, 2017, 11, 404-10.	0.6	10
100	Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population. Canadian Urological Association Journal, 2017, 11, 404-10. The Long-Term Effect of Radical Prostatectomy on Erectile Function, Urinary Continence, and Lower Urinary Tract Symptoms: A Comparison to Age-Matched Healthy Controls. BioMed Research International, 2017, 2017, 1-5.	0.6	10

	CHATION N	LPORT	
#	Article	IF	CITATIONS
103	Pelvic Radiation and Normal Tissue Toxicity. Seminars in Radiation Oncology, 2017, 27, 358-369.	2.2	56
104	Informed consent in randomised controlled trials: development and preliminary evaluation of a measure of Participatory and Informed Consent (PIC). Trials, 2017, 18, 327.	1.6	9
106	Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward. Tumori, 2017, 103, 395-404.	1.1	20
108	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. JAMA - Journal of the American Medical Association, 2018, 319, 883.	7.4	296
109	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 896.	7.4	252
110	The Patient-Reported Information Multidimensional Exploration (PRIME) Framework for Investigating Emotions and Other Factors of Prostate Cancer Patients with Low Intermediate Risk Based on Online Cancer Support Group Discussions. Annals of Surgical Oncology, 2018, 25, 1737-1745.	1.5	19
111	Quality of life up to 10Âyears after external beam radiotherapy and/or brachytherapy for prostate cancer. Brachytherapy, 2018, 17, 517-523.	0.5	9
112	Is radiotherapy the work of the devil?. BJU International, 2018, 121, 6-7.	2.5	4
113	Nanoparticleâ€based targeted cancer strategies for nonâ€invasive prostate cancer intervention. Journal of Cellular Physiology, 2018, 233, 6408-6417.	4.1	8
114	Longâ€ŧerm functional outcome analysis in a large cohort of patients after radical prostatectomy. Neurourology and Urodynamics, 2018, 37, 2263-2270.	1.5	15
115	Healthâ€related quality of life in active surveillance and radical prostatectomy for lowâ€risk prostate cancer: a prospective observational study (HAROW ―Hormonal therapy, Active Surveillance, Radiation,) Tj ETQ	<u>)</u> q0 Ձ Ֆ rg[3T /Øverlock 2
116	Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World Journal of Urology, 2018, 36, 1383-1389.	2.2	28
117	Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 66, 23-44.	7.7	38
118	Re: Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. European Urology, 2018, 74, 234.	1.9	2
119	Men's perceptions of the impact of the physical consequences of a radical prostatectomy on their quality of life: a qualitative systematic review. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 892-972.	1.7	20
120	Advancing the Quality of Care for Newly Diagnosed Prostate Cancer Patients: Novel Uses of Patient-Reported Outcomes. Annals of Surgical Oncology, 2018, 25, 1475-1477.	1.5	0
121	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. Cancer Causes and Control, 2018, 29, 383-388.	1.8	15
122	Focal Therapy in Primary Localised Prostate Cancer : The European Association of Urology Position in 2018. European Urology, 2018, 74, 84-91.	1.9	136

#	Article	IF	CITATIONS
123	Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data. BMJ Open, 2018, 8, e019409.	1.9	8
124	Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. Acta Oncológica, 2018, 57, 582-588.	1.8	17
125	Immunogenetics of prostate cancer: a still unexplored field of study. Pharmacogenomics, 2018, 19, 263-283.	1.3	3
126	Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study. Translational Behavioral Medicine, 2018, 8, 156-165.	2.4	9
127	Robot-assisted radical prostatectomy vs laparoscopic and open retropubic radical prostatectomy: functional outcomes 18 months after diagnosis from a national cohort study in England. British Journal of Cancer, 2018, 118, 489-494.	6.4	35
129	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology, 2018, 96, 35-46.	5.0	16
130	Worse Urinary, Sexual and Bowel Function Cause Emotional Distress and Vice Versa in Men Treated for Prostate Cancer. Journal of Urology, 2018, 199, 1464-1469.	0.4	15
131	Prostate Cancer. Medical Clinics of North America, 2018, 102, 215-229.	2.5	12
132	Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. Practical Radiation Oncology, 2018, 8, 206-212.	2.1	3
133	Sexual Recovery Following Prostate Cancer: Recommendations From 2ÂEstablished Canadian Sexual Rehabilitation Clinics. Sexual Medicine Reviews, 2018, 6, 279-294.	2.9	23
134	Outcomes and toxicities in patients with intermediateâ€risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy. BJU International, 2018, 121, 774-780.	2.5	12
135	¿Es útil el sistema transobturatriz ajustable ATOMS ® para el tratamiento de la incontinencia urinaria masculina en centros urológicos de bajo y medio volumen?. Actas Urológicas Españolas, 2018, 42, 267-272.	0.7	12
136	Incidencia real de cáncer de próstata en las áreas sanitarias de la comunidad autónoma de Castilla y León durante el año 2014. Datos del registro CAPCYL. Actas Urológicas Españolas, 2018, 42, 593-599.	0.7	2
137	A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 67-76.	1.6	19
138	Review of optimal techniques for robotic-assisted radical prostatectomy. Current Opinion in Urology, 2018, 28, 102-107.	1.8	3
139	Finding Value for Protons: The Case of Prostate Cancer?. Seminars in Radiation Oncology, 2018, 28, 131-137.	2.2	4
140	Functional outcomes of robot-assisted radical prostatectomy in patients eligible for active surveillance. World Journal of Urology, 2018, 36, 1391-1397.	2.2	4
141	Nomograms are key decision-making tools in prostate cancer radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 283-292.	1.6	29

#	Article	IF	CITATIONS
142	Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. European Urology, 2018, 74, 261-280.	1.9	82
143	A standardized analysis of the current surgical and non-surgical treatment selection process for men with localized prostate cancer. Journal of Robotic Surgery, 2018, 12, 215-221.	1.8	0
144	Prostate Cancer: Improving the Flow of Research. Radiology, 2018, 287, 5-9.	7.3	2
145	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 376-386.	0.8	7
146	Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. European Urology Focus, 2018, 4, 351-359.	3.1	32
147	Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. European Urology, 2018, 73, 11-20.	1.9	76
148	Longâ€ŧerm oncological outcomes and toxicity in 597 men aged â‰ ø 0Âyears at time of lowâ€doseâ€rate brachytherapy for localised prostate cancer. BJU International, 2018, 121, 38-45.	2.5	27
149	Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU International, 2018, 121, 61-68.	2.5	24
150	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. European Urology, 2018, 73, 156-165.	1.9	55
151	Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance. Journal of the National Cancer Institute, 2018, 110, 420-425.	6.3	17
152	Systematic Review of Decision Aids for the Management of Men With Localized Prostate Cancer. Urology, 2018, 114, 1-7.	1.0	14
153	Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 383-390.	0.8	7
154	The accuracy of patients' perceptions of the risks associated with localised prostate cancer treatments. BJU International, 2018, 121, 405-414.	2.5	15
155	2017 Update on Medical Overuse. JAMA Internal Medicine, 2018, 178, 110.	5.1	61
156	Summary statement on screening for prostate cancer in Europe. International Journal of Cancer, 2018, 142, 741-746.	5.1	29
157	Quality of life after brachytherapy or bilateral nerveâ€sparing robotâ€assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2018, 121, 540-548.	2.5	22
158	Decreasing suicide risk among patients with prostate cancer: Implications for depression, erectile dysfunction, and suicidal ideation screening. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 60-66.	1.6	50
159	Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients?. European Urology, 2018, 73, 33-37.	1.9	11

#	Article	IF	CITATIONS
160	Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer. European Urology, 2018, 73, 859-867.	1.9	33
161	A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Practical Radiation Oncology, 2018, 8, 40-47.	2.1	27
162	Decision aid use during postâ€biopsy consultations for localized prostate cancer. Health Expectations, 2018, 21, 279-287.	2.6	15
163	Depressive Symptoms and Low Sexual Desire after Radical Prostatectomy: Early and Long-Term Outcomes in a Real-Life Setting. Journal of Urology, 2018, 199, 474-480.	0.4	23
164	Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused Ultrasound. Journal of Urology, 2018, 199, 983-989.	0.4	67
165	Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030635.	6.2	128
166	Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer. European Urology, 2018, 73, 868-869.	1.9	3
167	Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals followâ€up study. Prostate, 2018, 78, 202-212.	2.3	7
168	Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance. Prostate Cancer and Prostatic Diseases, 2018, 21, 355-363.	3.9	2
169	Health-related-quality-of-life and toxicity after single fraction 19†Gy high-dose-rate prostate brachytherapy: Phase II trial. Radiotherapy and Oncology, 2018, 126, 278-282.	0.6	18
170	The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset. Supportive Care in Cancer, 2018, 26, 1297-1304.	2.2	19
171	Reproducibility in contouring the neurovascular bundle for prostate cancer radiation therapy. Practical Radiation Oncology, 2018, 8, e125-e131.	2.1	10
172	A Younger Man With Localized Prostate Cancer Asks, "Which Type of Radiation Is Right for Me?― Journal of Clinical Oncology, 2018, 36, 1780-1784.	1.6	1
173	Actual incidence of prostate cancer in healthcare areas of the autonomous community of Castilla–Leon during 2014. CAPCYL registry data. Actas Urológicas Españolas (English Edition), 2018, 42, 593-599.	0.2	0
174	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2018, 36, 1020-1044.	1.6	108
175	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. Journal of Clinical Oncology, 2018, 36, 3251-3258.	1.6	129
176	Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?. Journal of Clinical Oncology, 2018, 36, 2914-2917.	1.6	16
177	Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1823-1830.	1.6	70

#	ARTICLE	IF	Citations
180	Treatment Options in Oncology. JCO Clinical Cancer Informatics, 2018, 2, 1-10.	2.1	18
181	Prostate focal therapy. Current Opinion in Urology, 2018, 28, 512-521.	1.8	6
182	Impact of Pelvic Radiation Therapy on Inflatable Penile Prosthesis Reoperation Rates. Journal of Sexual Medicine, 2018, 15, 1653-1658.	0.6	3
183	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Frontiers in Oncology, 2018, 8, 397.	2.8	20
185	The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis. BMC Cancer, 2018, 18, 1015.	2.6	13
186	Dose to penile bulb is not associated with erectile dysfunction 18â€ ⁻ months post radiotherapy: A secondary analysis of a randomized trial. Clinical and Translational Radiation Oncology, 2018, 13, 50-56.	1.7	4
188	Machine learning to support social media empowered patients in cancer care and cancer treatment decisions. PLoS ONE, 2018, 13, e0205855.	2.5	56
189	Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ: British Medical Journal, 2018, 362, k3519.	2.3	319
190	Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ: British Medical Journal, 2018, 362, k3581.	2.3	110
191	What should doctors say to men asking for a PSA test?. BMJ: British Medical Journal, 2018, 362, k3702.	2.3	3
192	"Real-world―Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. European Urology, 2018, 74, 708-709.	1.9	0
193	Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. BMJ: British Medical Journal, 2018, 362, k3783.	2.3	7
194	Time for a "Radical―Change to Active Surveillance for Prostate Cancer?. European Urology, 2018, 74, 281-282.	1.9	4
196	Focal Treatment for Unilateral Prostate Cancer Using High-Intensity Focal Ultrasound: A Comprehensive Study of Pooled Data. Journal of Endourology, 2018, 32, 797-804.	2.1	16
198	Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. European Urology Oncology, 2018, 1, 353-360.	5.4	61
199	Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients. PLoS ONE, 2018, 13, e0194173.	2.5	24
200	Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort. Journal of Urology, 2018, 200, 1250-1255.	0.4	47
201	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. Current Urology Reports, 2018, 19, 68.	2.2	12

#	Article	IF	CITATIONS
202	A population-based study of the influence of socioeconomic status on prostate cancer diagnosis in Taiwan. International Journal for Equity in Health, 2018, 17, 79.	3.5	10
203	Survival outcomes of radical prostatectomy and external beam radiotherapy in clinically localized high-risk prostate cancer: a population-based, propensity score matched study. Cancer Management and Research, 2018, Volume 10, 1061-1067.	1.9	21
205	Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't!. Frontiers in Oncology, 2018, 8, 130.	2.8	4
206	Resveratrol treatment may preserve the erectile function after radiotherapy by restoring antioxidant defence mechanisms, SIRT1 and NOS protein expressions. International Journal of Impotence Research, 2018, 30, 179-188.	1.8	17
208	Screening for Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 1901.	7.4	876
209	Prostate-Specific Antigen–Based Screening for Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 1914.	7.4	367
210	"Give me five―ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach. Medical Oncology, 2018, 35, 96.	2.5	8
211	Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models. BMC Cancer, 2018, 18, 84.	2.6	30
212	Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial. BMC Cancer, 2018, 18, 64.	2.6	15
213	Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series. Health and Quality of Life Outcomes, 2018, 16, 21.	2.4	10
214	Health-related quality of life among long-term (≥5Âyears) prostate cancer survivors by primary intervention: a systematic review. Health and Quality of Life Outcomes, 2018, 16, 22.	2.4	24
215	A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients. Health and Quality of Life Outcomes, 2018, 16, 40.	2.4	8
217	Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients. European Urology, 2018, 74, 537-539.	1.9	7
218	Taking patient reported outcomes centre stage in cancer research – why has it taken so long?. Research Involvement and Engagement, 2018, 4, 25.	2.9	25
219	Is the adjustable transobturator system ATOMS ® useful for the treatment of male urinary incontinence in low to medium volume urological centers?. Actas Urológicas Españolas (English) Tj ETQq0 0 0	rgðīÞ/Ovei	laack 10 Tf 5
220	A biological modelling based comparison of radiotherapy plan robustness using photons vs protons for focal prostate boosting. Physics and Imaging in Radiation Oncology, 2018, 6, 101-105.	2.9	4
221	Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking. Advances in Radiation Oncology, 2018, 3, 630-638.	1.2	13
222	Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome. Cancer Management and Research, 2018, Volume 10, 473-480.	1.9	15

#	Article	IF	CITATIONS
224	Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature. European Urology Oncology, 2018, 1, 283-291.	5.4	14
225	How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016–2017. European Urology, 2019, 75, 25-31.	1.9	8
226	Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology, 2019, 124, 98-106.	1.0	9
228	Sexual Health Recovery For Prostate Cancer Survivors: The Proposed Role Of Acceptance And Mindfulness-Based Interventions. Sexual Medicine Reviews, 2019, 7, 627-635.	2.9	11
229	Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy. Frontiers in Oncology, 2019, 9, 638.	2.8	7
230	Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer. JAMA Network Open, 2019, 2, e198427.	5.9	47
233	Severe Preoperative Symptoms Delay Readiness to Return to Intended Oncologic Therapy (RIOT) After Liver Resection. Annals of Surgical Oncology, 2019, 26, 4548-4555.	1.5	7
234	Development and validation of a patient decision aid for prostate Cancer therapy: from paternalistic towards participative shared decision making. BMC Medical Informatics and Decision Making, 2019, 19, 130.	3.0	26
235	The association between elevated serum oestradiol levels and clinically significant erectile dysfunction in men presenting for andrological evaluation. Andrologia, 2019, 51, e13345.	2.1	11
236	Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 713-722.	0.8	29
237	Decision Support Systems in Prostate Cancer Treatment: An Overview. BioMed Research International, 2019, 2019, 1-10.	1.9	19
238	Exercise duRing Active Surveillance for prostatE cancer—the ERASE trial: a study protocol of a phase Il randomised controlled trial. BMJ Open, 2019, 9, e026438.	1.9	10
239	MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1045-1053.	0.8	26
240	The EORTC quality of life questionnaire predicts early and long-term incontinence in patients treated with robotic assisted radical prostatectomy: Analysis of a large single center cohort. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 1006-1013.	1.6	8
241	Factors associated with exercise preferences, barriers and facilitators of prostate cancer survivors. European Journal of Cancer Care, 2019, 28, e13135.	1.5	22
242	Usefulness of a novel classification based on perioperative changes of membranous urethral length using hierarchical cluster analysis of urinary incontinence and overactive bladder symptoms after robotâ€essisted radical prostatectomy: A prospective observational study. Neurourology and Urodynamics. 2019. 38. 2200-2208.	1.5	3
244	<p>Shared decision making for men facing prostate cancer treatment: a systematic review of randomized controlled trials</p> . Patient Preference and Adherence, 2019, Volume 13, 1153-1174.	1.8	16
245	Increasing the use of active surveillance for prostate cancer in younger men. Cancer, 2019, 125, 3292-3295.	4.1	6

#	Article		CITATIONS
246	Patientâ€reported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a populationâ€based prospective cohort. Cancer, 2019, 125, 3657-3665.		9
247	Radiation therapy for prostate cancer: An evolving treatment modality. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 579-581.	1.6	2
248	Acceptance and Commitment Therapy to Increase Adherence to Penile Injection Therapy-Based Rehabilitation After Radical Prostatectomy: Pilot Randomized Controlled Trial. Journal of Sexual Medicine, 2019, 16, 1398-1408.	0.6	16
249	Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study. BMC Cancer, 2019, 19, 947.	2.6	4
250	A Randomized Double-blind Placebo-controlled Trial on the Effect of Magnesium Oxide in Patients With Chronic Constipation. Journal of Neurogastroenterology and Motility, 2019, 25, 563-575.	2.4	23
252	A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer. BJU International, 2019, 124, 31-36.	2.5	27
253	Long-term clinical outcomes of 538 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Journal of Radiation Oncology, 2019, 8, 311-321.	0.7	0
255	<p>Imaging-Based Individualized Response Prediction Of Carbon Ion Radiotherapy For Prostate Cancer Patients</p> . Cancer Management and Research, 2019, Volume 11, 9121-9131.	1.9	18
256	Obesity and psychosocial wellâ€being among cancer patients and survivors. Psycho-Oncology, 2019, 28, 2141-2148.	2.3	6
257	Patient-reported outcomes after open radical prostatectomy, laparoscopic radical prostatectomy and permanent prostate brachytherapy. Japanese Journal of Clinical Oncology, 2019, 49, 1037-1042.	1.3	6
258	Quality of life outcomes after low doseâ€rate brachytherapy for localized prostate cancer: Current status and future perspectives. International Journal of Urology, 2019, 26, 1099-1105.	1.0	2
259	Quality of Life–Focused Decision-Making for Prostate Cancer. Current Urology Reports, 2019, 20, 57.	2.2	15
260	Elective Node Irradiation With Integrated Boost to the Prostate Using Helical IMRT–Clinical Outcome of the Prospective PLATIN-1 Trial. Frontiers in Oncology, 2019, 9, 751.	2.8	6
261	Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. International Journal of Hyperthermia, 2019, 36, 914-924.	2.5	6
262	Focal High-intensity Focussed Ultrasound Partial Gland Ablation for the Treatment of Localised Prostate Cancer: A Report of Medium-term Outcomes From a Single-center in the United Kingdom. Urology, 2019, 133, 175-181.	1.0	26
263	Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer. Health and Quality of Life Outcomes, 2019, 17, 147.	2.4	8
264	Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology, The, 2019, 20, 1531-1543.	10.7	362
265	Has Robotic Surgery Improved Erectile Function Recovery Rates in Radical Prostatectomy Patients?. Journal of Sexual Medicine, 2019, 16, 1487-1489.	0.6	0

#	Article		CITATIONS
266	Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. Scandinavian Journal of Urology, 2019, 53, 295-302.	1.0	23
267	The Quality of Life among Men Receiving Active Surveillance for Prostate Cancer: An Integrative Review. Healthcare (Switzerland), 2019, 7, 14.	2.0	10
268	The importance of sexuality, changes in erectile functioning and its association with self-esteem in men with localized prostate cancer: data from an observational study. BMC Urology, 2019, 19, 9.	1.4	8
269	Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy. Practical Radiation Oncology, 2019, 9, e172-e179.	2.1	20
270	Patient Experience of Thyroid Cancer Active Surveillance in Japan. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 363.	2.2	81
271	Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. Lancet Oncology, The, 2019, 20, 436-447.	10.7	100
272	A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World Journal of Urology, 2019, 37, 2099-2108.	2.2	4
273	Mild hyperthermia as a localized radiosensitizer for deep-seated tumors: investigation in an orthotopic prostate cancer model in mice. British Journal of Radiology, 2019, 92, 20180759.	2.2	11
274	Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2019, 76, 284-303.		153
275	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology Biology Physics, 2019, 104, 778-789.	0.8	247
276	†l'm not a chance taker': A mixed methods exploration of factors affecting prostate cancer treatment decision-making. Ethnicity and Health, 2021, 26, 1143-1162.	2.5	12
277	Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review. BMJ Open, 2019, 9, e029149.	1.9	15
279	Health-related quality of life ofÂexposed versus non-exposed androgen deprivation therapyÂpatients with prostate cancer: a cross-sectional study. International Journal of Clinical Pharmacy, 2019, 41, 993-1003.	2.1	6
280	The psychological impact of being on a monitoring pathway for localised prostate cancer: A UKâ€wide mixed methods study. Psycho-Oncology, 2019, 28, 1567-1575.	2.3	6
281	REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 2019, 138, 59-67.	0.6	53
282	Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities. International Journal of Urology, 2019, 26, 950-954.	1.0	17
283	Validated Prospective Assessment of Quality of Life After Robot-Assisted Laparoscopic Prostatectomy: Beyond Continence and Erections. American Journal of Men's Health, 2019, 13, 155798831985455.	1.6	7
284	Use and early mortality outcomes of active surveillance in patients with intermediateâ€risk prostate cancer. Cancer, 2019, 125, 3164-3171.	4.1	35

ARTICLE IF CITATIONS Updated recommendations of the International Society of Geriatric Oncology on prostate cancer 285 2.8 134 management in older patients. European Journal of Cancer, 2019, 116, 116-136. Change in Functional Status After Prostate Cancer Treatment Among Medicare Advantage 1.0 Beneficiaries. Urology, 2019, 131, 104-111. Pharmacist–Patient Communication in Prostate Cancer as a Strategy to Humanize Health Care: A 287 0.9 6 Qualitative Study. Journal of Patient Experience, 2019, 6, 150-156. The Patient Journey in Prostate Cancer: Key Points for Nurses. Principles of Specialty Nursing, 2019, , 0.2 195-213. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series. CardioVascular and 289 2.0 21 Interventional Radiology, 2019, 42, 1405-1412. Contemporary approach to active surveillance for favorable risk prostate cancer. Asian Journal of Urology, 2019, 6, 146-152. 290 1.2 Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United 291 1.9 6 Kingdom. European Urology, 2019, 76, 228-237. Key factors associated with social distress after prostate cancer: Results from the United Kingdom Lifé after Prostate Cancer diagnosis study. Cancer Epidemiology, 2019, 60, 201-207. Weakly supervised natural language processing for assessing patient-centered outcome following 293 2.0 35 prostate cancer treatment. JAMIA Open, 2019, 2, 150-159. Radical prostatectomy or radiotherapy for highâ€and very highâ€risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU International, 2019, 124, 2.5 811-819. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A 296 0.9 6 planning feasibility study. Medical Dosimetry, 2019, 44, 356-364. Healthâ€related quality of life in longâ€term survivors with localised prostate cancer by 1.5 therapy—Result's from a populationa€based study. European Journal of Cancer Care, 2019, 28, e13076. Predicting trajectories of recovery in prostate cancer patients undergone Robot-Assisted Radical 298 2.5 15 Prostatectomy (RARP). PLoS ONÉ, 2019, 14, e0214682. Maximizing rectal dose sparing with hydrogel: A retrospective planning study. Journal of Applied Clinical Medical Physics, 2019, 20, 91-98. 299 A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 300 1.9 5 2019, 17, e472-e481. Does Interfraction Cone Beam Computed Tomography Improve Target Localization in Prostate Bed Radiotherapy?. Technology in Cancer Research and Treatment, 2019, 18, 153303381983196. Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with 303 1.9 11 Localized Prostate Cancer. European Urólogy, 2019, 76, 391-397. Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external 304 8.4 validation of the PREDICT Prostate multivariable model. PLoS Medicine, 2019, 16, e1002758.

#	Article	IF	CITATIONS
305	Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015. Yonsei Medical Journal, 2019, 60, 257.	2.2	5
306	STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 33-35.	0.8	8
307	Morphologic changes after bladder neck intussusception in laparoscopic radical prostatectomy contribute to early postoperative continence. International Urology and Nephrology, 2019, 51, 1157-1165.	1.4	1
308	Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. Radiotherapy and Oncology, 2019, 134, 204-210.	0.6	5
309	Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology, 2019, 37, 964-973.	1.6	35
310	Patientâ€reported outcomes and urodynamic findings in men with persistent lower urinary tract symptoms following robotâ€assisted radical prostatectomy. Neurourology and Urodynamics, 2019, 38, 1353-1362.	1.5	9
311	Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study. Clinical and Translational Oncology, 2019, 21, 1673-1679.	2.4	0
312	Determinants of quality prostate cancer survivorship care across the primary and specialty care interface: Lessons from the Veterans Health Administration. Cancer Medicine, 2019, 8, 2686-2702.	2.8	6
313	Intensive Triangulation of Qualitative Research and Quantitative Data to Improve Recruitment to Randomized Trials: The QuinteT Approach. Qualitative Health Research, 2019, 29, 672-679.	2.1	38
314	Linking surgical skills to postoperative outcomes: a Delphi study on the robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2019, 13, 675-687.	1.8	6
315	Hydro-Jet Dissection of the Cavernous Nerves Preserves Erection Function in a Radical Prostatectomy Animal Model. Sexual Medicine, 2019, 7, 104-110.	1.6	1
316	Robot or radiation? A qualitative study of the decision support needs of men with localised prostate cancer choosing between robotic prostatectomy and radiotherapy treatment. Patient Education and Counseling, 2019, 102, 1364-1372.	2.2	14
317	Mediumâ€ŧerm oncological outcomes in a large cohort of men treated with either focal or hemiâ€∎blation using highâ€intensity focused ultrasonography for primary localized prostate cancer. BJU International, 2019, 124, 431-440.	2.5	93
318	Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy. JAMA Oncology, 2019, 5, 664.	7.1	40
319	The Precision Prostatectomy: an IDEAL Stage 0, 1 and 2a Study. BMJ Surgery, Interventions, and Health Technologies, 2019, 1, e000002.	0.9	7
320	Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible overdiagnosis. BMJ Open, 2019, 9, e026960.	1.9	12
321	Prostate cancer treatment choices: the GP's role in shared decision making. British Journal of General Practice, 2019, 69, 588-589.	1.4	0
322	Risk of Depression After Radical Prostatectomy—A Nationwide Registry-based Study. European Urology Oncology, 2021, 4, 601-608.	5.4	13

#	Article		CITATIONS
323	Patient-Centered Outcomes in Radiation Oncology. Hematology/Oncology Clinics of North America, 2019, 33, 1105-1116.	2.2	5
324	High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores. Brachytherapy, 2019, 18, 793-799.	0.5	8
325	Why men with a low-risk prostate cancer select and stay on active surveillance: A qualitative study. PLoS ONE, 2019, 14, e0225134.	2.5	11
326	Predictors for lower urinary tract symptoms and the urinary specific quality of life in prostate cancer patients. Journal of the Chinese Medical Association, 2019, 82, 482-487.	1.4	4
327	Men's perceptions of the impact of the physical consequences of a radical prostatectomy on their quality of life. International Journal of Evidence-Based Healthcare, 2019, 17, S41-S42.	0.5	6
328	PSA testing: a personal view. British Journal of General Practice, 2019, 69, 562-562.	1.4	3
329	Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. European Urology, 2019, 75, 221-228.	1.9	72
330	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	2.2	21
331	Proton therapy for prostate cancer: A review of the rationale, evidence, and current state. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 628-636.	1.6	20
332	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. Journal of Clinical Epidemiology, 2019, 106, 108-120.	5.0	49
333	Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within aÂrandomized controlled trial. Strahlentherapie Und Onkologie, 2019, 195, 393-401.	2.0	39
334	Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. Nature Reviews Clinical Oncology, 2019, 16, 168-184.	27.6	41
335	Retzius-sparing versus standard robot-assisted radical prostatectomy: a prospective randomized comparison on immediate continence rates. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 2187-2196.	2.4	76
336	Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. Health and Quality of Life Outcomes, 2019, 17, 11.	2.4	17
337	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells, 2019, 8, 43.	4.1	38
338	Functional results in the treatment of localized prostate cancer. An updated literature review. Revista Internacional De AndrologÃa, 2019, 17, 143-154.	0.3	1
339	Depression and prostate cancer: A focused review for the clinician. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 282-288.	1.6	62
340	Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA). BMC Medical Informatics and Decision Making, 2019, 19, 2.	3.0	20

		ATION REPORT	
#	Article	IF	CITATIONS
341	Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results From a National Survey of Radiation Oncologists and Urologists. Annals of Surgical Oncology, 2019, 26, 660-668.	1.5	10
342	Comparison of adjustable male slings and artificial urinary sphincter in the treatment of male urinary incontinence: a retrospective analysis of patient selection and postoperative continence status. World Journal of Urology, 2019, 37, 1415-1420.	2.2	11
343	Stereotactic Radiosurgery for Prostate Cancer. , 2019, , .		1
344	Gynecologic radiation oncology patients report unmet needs regarding sexual health communication with providers. Journal of Cancer Research and Clinical Oncology, 2019, 145, 495-502.	2.5	19
345	Conservative management and radical treatment in localised prostate cancer: A systematic review with meta-analysis and trial sequential analysis. Journal of Clinical Urology, 2019, 12, 228-238.	0.1	0
346	Biochemical and magnetic resonance image response in targeted focal cryotherapy to ablate targeted biopsyâ€proven index lesion of prostate cancer. International Journal of Urology, 2019, 26, 317-319.	1.0	8
347	Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. European Urology, 2019, 75, 3-7.	1.9	10
348	Psychological impact of different primary treatments for prostate cancer: A critical analysis. Andrologia, 2019, 51, e13157.	2.1	39
349	Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement: A Structured Review. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 217-226.	0.7	7
350	Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 324-330.	1.6	11
351	Quality of Life After Open Radical Prostatectomy Compared with Robot-assisted Radical Prostatectomy. European Urology Focus, 2019, 5, 389-398.	3.1	38
352	Evidence-based approach to active surveillance of prostate cancer. World Journal of Urology, 2020, 38, 555-562.	2.2	9
353	Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. European Urology Oncology, 2020, 3, 640-647.	5.4	15
354	Comparison of longitudinal health-related quality-of-life outcomes between anterior and posterior surgical approaches to robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2020, 14, 255-260.	1.8	4
355	Patient-Reported Outcomes: Understanding Surgical Efficacy and Quality from the Patient's Perspective. Annals of Surgical Oncology, 2020, 27, 56-64.	1.5	26
356	The Trigger Project: The Challenge of Introducing Electronic Patient-Reported Outcome Measures Into a Radiotherapy Service. Clinical Oncology, 2020, 32, e76-e79.	1.4	7
357	Advanced Reconstruction of Vesicourethral Support (ARVUS) during robot-assisted radical prostatectomy: first independent evaluation and review of other factors influencing 1Âyear continence outcomes. World Journal of Urology, 2020, 38, 1933-1941.	2.2	5
358	Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices. European Urology Oncology, 2020, 3, 21-31.	5.4	63

#	Article	IF	CITATIONS
359	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer and Prostatic Diseases, 2020, 23, 179-183.	3.9	12
360	A Systematic Review of Sexual Satisfaction in Prostate Cancer Patients. Sexual Medicine Reviews, 2020, 8, 450-465.	2.9	6
361	Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy. Inflammatory Bowel Diseases, 2020, 26, 728-733.	1.9	18
362	Development and Initial Evaluation of a Multifaceted Intervention to Improve Mental Health and Quality of Life Among Prostate Cancer Survivors. International Journal of Mental Health and Addiction, 2020, 18, 1067-1080.	7.4	13
363	The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. Prostate Cancer and Prostatic Diseases, 2020, 23, 144-150.	3.9	9
364	Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clinical Chemistry and Laboratory Medicine, 2020, 58, 326-339.	2.3	123
365	Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 225-230.	1.6	19
366	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU International, 2020, 125, 506-514.	2.5	32
368	Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis. World Journal of Urology, 2020, 38, 2477-2484.	2.2	16
369	Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer. Urology, 2020, 135, 111-116.	1.0	0
370	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 83-93.	1.6	24
371	Functional Recovery Following Primary Treatment for Prostate Cancer: Update from the CEASAR Study. European Urology Focus, 2020, 6, 205-207.	3.1	4
372	Developments in MRI-targeted prostate biopsy. Current Opinion in Urology, 2020, 30, 1-8.	1.8	10
373	Sexual function outcomes following interventions for prostate cancer: are contemporary reports on functional outcomes misleading?. International Journal of Impotence Research, 2020, 32, 495-502.	1.8	8
374	Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial. Supportive Care in Cancer, 2020, 28, 3331-3342.	2.2	12
375	Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). Cancer Epidemiology, 2020, 64, 101623.	1.9	14
376	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. European Urology, 2020, 77, 320-330.	1.9	107
377	Current Mental Distress Among Men With a History of Radical Prostatectomy and Related Adverse Correlates. American Journal of Men's Health, 2020, 14, 155798832095753.	1.6	16

#	Article		CITATIONS
378	Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. BMJ, The, 2020, 371, m3503.	6.0	43
379	Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners. Journal of Cancer Survivorship, 2020, 15, 536-545.	2.9	2
380	Differences in treatment choices for localised prostate cancer diagnosed in private and public health services. Medical Journal of Australia, 2020, 213, 411-417.	1.7	14
381	Influence of deprivation and rurality on patient-reported outcomes of men living with and beyond prostate cancer diagnosis in the UK: A population-based study. Cancer Epidemiology, 2020, 69, 101830.	1.9	6
383	A Narrative Overview of Active Surveillance for Clinically Localised Prostate Cancer. Seminars in Oncology Nursing, 2020, 36, 151045.	1.5	3
384	Health-Related Quality of Life and Survival in Prostate Cancer Patients in a Real-World Setting. Urologia Internationalis, 2020, 104, 939-947.	1.3	4
385	Secondary malignancies after radiation therapy in prostate cancer survivors: a propensity-score matched competing-risk analysis. Translational Cancer Research, 2020, 9, 2847-2854.	1.0	0
386	Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 735.e17-735.e25.	1.6	19
387	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. European Urology Open Science, 2020, 21, 1-4.	0.4	1
388	Comparing bowel and urinary domains of patientâ€reported quality of life at the end of and 3 months post radiotherapy between intensityâ€modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. Cancer Medicine, 2020, 9, 7925-7934.	2.8	6
389	Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients. European Urology Focus, 2021, 7, 987-994.	3.1	23
391	Association between masturbation and functional outcome in the postoperative course after nerve-sparing radical prostatectomy. Translational Andrology and Urology, 2020, 9, 1286-1295.	1.4	0
392	Rethinking prostate cancer screening: could MRI be an alternative screening test?. Nature Reviews Urology, 2020, 17, 526-539.	3.8	19
393	Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: Medium-term results from a single centre. PLoS ONE, 2020, 15, e0236026.	2.5	7
394	Prostate cancer screening and treatment: where have we come from and where are we going?. BJU International, 2020, 126, 218-224.	2.5	39
395	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. British Journal of Cancer, 2020, 123, 1063-1070.	6.4	15
396	Retziusâ€sparing robotâ€assisted radical prostatectomy improves early recovery of urinary continence: a randomized, controlled, singleâ€blind trial with a 1â€year followâ€up. BJU International, 2020, 126, 633-640.	2.5	33
397	Digital application developed to evaluate functional results following robot-assisted radical prostatectomy. Computer Methods and Programs in Biomedicine, 2020, 197, 105683.	4.7	7

#	Article	IF	CITATIONS
398	Depression and prostate cancer: implications for urologists and oncologists. Nature Reviews Urology, 2020, 17, 571-585.	3.8	13
399	Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy, 2020, 19, 574-583.	0.5	13
400	Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study. BMC Cancer, 2020, 20, 757.	2.6	15
402	<p>The Impact of Prostate Cancer Treatment on Quality of Life: A Narrative Review with a Focus on Randomized Data</p> . Research and Reports in Urology, 2020, Volume 12, 533-546.	1.0	9
403	Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial. BMC Cancer, 2020, 20, 971.	2.6	7
404	Clinic Utilization and Characteristics of Patients Accessing a Prostate Cancer Supportive Care Program's Sexual Rehabilitation Clinic. Journal of Clinical Medicine, 2020, 9, 3363.	2.4	2
405	Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imaging–targeted Biopsy: A Large Multicenter Cohort Study. European Urology Focus, 2021, 7, 1002-1010.	3.1	11
406	Effects of nerveâ€sparing procedures on bowel function after robotâ€assisted radical prostatectomy: A longitudinal study. International Journal of Medical Robotics and Computer Assisted Surgery, 2020, 16, 1-10.	2.3	3
407	Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study. BMJ Open, 2020, 10, e032914.	1.9	2
408	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. BMJ Open, 2020, 10, e036024.	1.9	7
409	Investigating the impact of open label design on patientâ€reported outcome results in prostate cancer randomized controlled trials. Cancer Medicine, 2020, 9, 7363-7374.	2.8	19
410	Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. International Journal of Urology, 2020, 27, 882-889.	1.0	12
411	Multiparametric prostate MRI-based intensity-modulated radiation therapy guided by prostatic calcifications. British Journal of Radiology, 2020, 93, 20200571.	2.2	1
412	Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Practical Radiation Oncology, 2020, 10, 282-292.	2.1	5
414	MR Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial. Journal of Vascular and Interventional Radiology, 2020, 31, 740-746.e4.	0.5	7
416	Quality of life and adjustment in men with prostate cancer: Interplay of stress, threat and resilience. PLoS ONE, 2020, 15, e0239469.	2.5	15
417	Health-Related Quality of Life and Patient-Reported Outcomes in Radiation Oncology Clinical Trials. Current Treatment Options in Oncology, 2020, 21, 87.	3.0	6
418	Evaluation of Patient-Reported Outcomes in Burn Survivors Undergoing Reconstructive Surgery in the Rehabilitative Period. Plastic and Reconstructive Surgery, 2020, 146, 171-182.	1.4	10

#	Article	IF	CITATIONS
419	Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. Advances in Radiation Oncology, 2020, 5, 1225-1231.	1.2	0
420	Asian-American Race and Urinary Continence After Radical Prostatectomy. European Urology Open Science, 2020, 22, 51-53.	0.4	3
421	Width of spared neurovascular bundle after robot-assisted laparoscopic prostatectomy in patients with prostate cancer: is it a reliable factor for predicting postoperative sexual outcome?. Prostate International, 2020, 9, 119-124.	2.3	2
422	Dynamic contrast enhancement in prostate MRI as predictor of erectile function and recovery after radical prostatectomy. Aging Male, 2020, 23, 1518-1526.	1.9	1
423	Active surveillance in prostate cancer is possible for Afro-Caribbean population: Comparison of oncological outcomes with a Caucasian cohort. Progres En Urologie, 2020, 30, 532-540.	0.8	1
424	Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities). Reports of Practical Oncology and Radiotherapy, 2020, 25, 367-375.	0.6	14
425	Radical prostatectomy versus brachytherapy for clinically localized prostate cancer on oncological and functional outcomes: a meta-analysis. Translational Andrology and Urology, 2020, 9, 332-343.	1.4	13
426	Feasibility and safety of 1.5ÂT MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2379-2397.	2.5	25
427	Unmet expectations in prostate cancer patients and their association with decision regret. Journal of Cancer Survivorship, 2020, 14, 731-738.	2.9	19
428	Challenging the Norm: What Level of Evidence Is Necessary to Adopt Postprostatectomy Hypofractionated Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2020, 107, 297-298.	0.8	4
429	The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. European Urology, 2020, 78, 155-160.	1.9	18
430	Healthâ€related quality of life in longâ€term prostate cancer survivors after nerveâ€sparing and nonâ€nerveâ€sparing radical prostatectomy—Results from the multiregional PROCAS study. Cancer Medicine, 2020, 9, 5416-5424.	2.8	6
431	In reply to Egger et al.: Lack of benefit from adjuvant postoperative radiotherapy and issues raised about upfront management of high―and veryâ€high―isk prostate cancer patients. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 595-596.	1.8	0
432	Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 846.e9-846.e16.	1.6	20
433	Comparative Effectiveness of Radiotherapy versus Focal Laser Ablation in Patients with Low and Intermediate Risk Localized Prostate Cancer. Scientific Reports, 2020, 10, 9112.	3.3	6
434	Radical prostatectomy versus deferred treatment for localised prostate cancer. The Cochrane Library, 2020, 6, CD006590.	2.8	23
435	Reconsidering the Trade-offs of Prostate Cancer Screening. New England Journal of Medicine, 2020, 382, 2465-2468.	27.0	53
436	Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. European Urology, 2020, 78, 371-378.	1.9	66

#	Article	IF	CITATIONS
437	Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 930-935.		12
438	The effect of radiation therapy on post-prostatectomy urinary function. Reports of Practical Oncology and Radiotherapy, 2020, 25, 442-446.	0.6	4
439	The Radiation Oncology trainee research programme is working well, so can anything else be done to help our trainees acquire research skills?. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 303-305.	1.8	1
440	Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?. Cancers, 2020, 12, 635.	3.7	6
441	Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clinical Genitourinary Cancer, 2020, 18, 274-283.e5.	1.9	11
442	Quality of life in active surveillance for early prostate cancer. International Journal of Urology, 2020, 27, 296-306.	1.0	9
443	Development of a multivariable risk model integrating urinary cell DNA methylation and cellâ€free RNA data for the detection of significant prostate cancer. Prostate, 2020, 80, 547-558.	2.3	17
444	1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiation Oncology, 2020, 15, 69.	2.7	94
445	A Cost-Effectiveness and Quality of Life Analysis of Different Approaches to the Management and Treatment of Localized Prostate Cancer. Frontiers in Oncology, 2020, 10, 103.	2.8	5
446	Health-related quality of life in Japanese patients with prostate cancer following proton beam therapy: an institutional cohort study. Japanese Journal of Clinical Oncology, 2020, 50, 519-527.	1.3	2
447	Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer. Japanese Journal of Clinical Oncology, 2020, 50, 963-969.	1.3	5
448	Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. Lancet, The, 2020, 396, 50-61.	13.7	22
449	ICS 2020 LAS VEGAS SCIENTIFIC PROGRAMME. Neurourology and Urodynamics, 2020, 39, S1-S495.	1.5	0
450	Patient preferences for reducing bowel adverse events following prostate radiotherapy. PLoS ONE, 2020, 15, e0235616.	2.5	2
451	Incidence and impact of acute urinary retention after robot-assisted radical prostatectomy. Prostate International, 2020, 8, 121-124.	2.3	2
452	Design of the PROstate cancer follow-up care in Secondary and Primary hEalth Care study (PROSPEC): a randomized controlled trial to evaluate the effectiveness of primary care-based follow-up of localized prostate cancer survivors. BMC Cancer, 2020, 20, 635.	2.6	6
454	Use of psychoâ€oncological services by prostate cancer patients: A multilevel analysis. Cancer Medicine, 2020, 9, 3680-3690.	2.8	11
455	Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part II on Urological Management). Reports of Practical Oncology and Radiotherapy, 2020, 25, 619-624.	0.6	7

		CITATION REPO	ORT	
#	Article	IF	F	CITATIONS
456	Active surveillance for prostate cancer: an update. Trends in Urology & Men's Health, 2020, 11,	8-11. 0).4	0
458	Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). European Urology, 2020, 713-724.		.9	108
459	Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowe Function Longitudinally After Radiation Therapy, Surgery, or Observation. European Urology, 20 248-255.		.9	12
460	A qualitative study exploring men's experience of sexual dysfunction as a result of radiothe androgen deprivation therapy to treat prostate cancer. Radiography, 2020, 26, S16.	rapy and 2	.1	2
461	Clinical Outcomes of Dose-escalated Radiotherapy for Localised Prostate Cancer: A Single-instit Experience. In Vivo, 2020, 34, 757-765.	ution 1	.3	4
462	Development of a conceptual framework to improve sexual wellbeing communication in routin prostate cancer care. Patient Education and Counseling, 2020, 103, 1150-1160.	2 2	.2	6
463	Longâ€ŧerm oncological and functional followâ€up in lowâ€doseâ€rate brachytherapy for pros results from the prospective nationwide Swiss registry. BJU International, 2020, 125, 827-835.	tate cancer: 2	2.5	7
464	The Precision Prostatectomy: "Waiting for Godotâ€: European Urology Focus, 2020, 6, 227	-230. 3	.1	9
465	Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, o External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 149.	2	.4	172
466	Comparing Radiotherapy to Prostatectomy for High-Risk Prostate Cancer. Cancer Journal (Sudb	ury,) Tj ETQq1 1 0.78 2	34314 rg 0	ßT /Overl⊙ 2
467	Early Mortality of Prostatectomy vs. Radiotherapy as a Primary Treatment for Prostate Cancer: Population-Based Study From the United States and East Germany. Frontiers in Oncology, 201	а Э, 9, 1451. ²	2.8	0
468	Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial. Frontiers in Oncolog 2020, 10, 469.		8	16
469	Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09. Clinical and Translat Radiation Oncology, 2020, 22, 50-54.	ional 1	.7	5
470	Work status and work ability after radical prostatectomy or active surveillance for prostate can Scandinavian Journal of Urology, 2020, 54, 194-200.	cer. 1	.0	5
471	Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation thera for localized prostate cancer: A systematic review and meta-analysis of phase III randomized tria Radiotherapy and Oncology, 2020, 148, 235-242.).6	33
472	Examined and Positive Lymph Node Counts Are Associated with Mortality in Prostate Cancer: A Population-Based Analysis. Urologia Internationalis, 2020, 104, 699-709.	1	.3	6
473	Superior early and long-term continence following early micturition on day 2 after robot-assister radical prostatectomy: a randomized prospective trial. World Journal of Urology, 2021, 39, 771		2.2	4
474	A discussion on controversies and ethical dilemmas in prostate cancer screening. Journal of Me Ethics, 2021, 47, 152-158.	dical 1	.8	11

#	Article		CITATIONS
475	Age-related urologic problems in the complex urologic patient. World Journal of Urology, 2021, 39, 1037-1044.		6
476	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	1.9	1,545
477	Management of voiding dysfunction associated with pelvic malignancies. International Journal of Urology, 2021, 28, 17-24.	1.0	1
478	Early Effects of High-intensity Focused Ultrasound (HIFU) Treatment for Prostate Cancer on Fecal Continence and Anorectal Physiology. Urology, 2021, 148, 211-216.	1.0	0
479	Gain–loss framing and patients' decisions: a linguistic examination of information framing in physician–patient conversations. Journal of Behavioral Medicine, 2021, 44, 38-52.	2.1	5
480	A qualitative study exploring men's experience of sexual dysfunction as a result of radiotherapy and androgen deprivation therapy to treat prostate cancer. Journal of Radiotherapy in Practice, 2021, 20, 39-42.	0.5	5
481	Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial. European Urology, 2021, 79, 188-197.	1.9	29
482	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part Il—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 2021, 79, 263-282.	1.9	633
483	Quality-of-life Benefits and Harms from Prostate Radiotherapy in Patients with Low-burden Metastatic Prostate Cancer. European Urology, 2021, 79, 198-199.	1.9	0
484	Evaluation of longâ€ŧerm living conditions in patients treated for localised prostate cancer. European Journal of Cancer Care, 2021, 30, e13333.	1.5	0
485	Does radical prostatectomy result in lower urinary tract symptom improvement in high-risk and locally advanced prostate cancer? A Single-center experience. Urologia, 2021, 88, 110-114.	0.7	1
486	Influence of Geography on Prostate Cancer Treatment. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1286-1295.	0.8	19
487	Neglected side effects to curative prostate cancer treatments. International Journal of Impotence Research, 2021, 33, 428-438.	1.8	18
488	Differences in Use of Aggressive Therapy for Localized Prostate Cancer in New York City. Clinical Genitourinary Cancer, 2021, 19, e55-e62.	1.9	1
489	Urinary Outcomes for Men With High Baseline International Prostate Symptom Scores Treated With Prostate SBRT. Advances in Radiation Oncology, 2021, 6, 100582.	1.2	3
490	Beyond morbidity and mortality: The practicality of measuring patient-reported outcomes in trauma. Injury, 2021, 52, 127-133.	1.7	5
491	The EPIC-26 domain scores after radical prostatectomy are associated with the personality trait of neuroticism. International Urology and Nephrology, 2021, 53, 691-698.	1.4	4
492	Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. British Journal of Radiology, 2021, 94, 20200848.	2.2	28

	CITATION	CITATION REPORT	
#	Article	IF	CITATIONS
493	The Prepare for Kidney Care Study: prepare for renal dialysis versus responsive management in advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 975-982.	0.7	16
494	Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). Journal of Cancer Research and Clinical Oncology, 2021, 147, 235-242.	2.5	9
495	MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218). European Radiology, 2021, 31, 716-728.	4.5	31
496	Prostatectomy Versus Observation for Localized Prostate Cancer: A Meta-Analysis. Scandinavian Journal of Surgery, 2021, 110, 78-85.	2.6	1
497	Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. European Urology Focus, 2021, 7, 301-308.	3.1	11
498	How to implement the requirements of a quality assurance system for prostate cancer. World Journal of Urology, 2021, 39, 41-47.	2.2	1
499	Actualización y optimización de la vigilancia activa en cáncer de próstata en 2021. Actas Urológicas Españolas, 2021, 45, 1-7.	0.7	9
500	Strahlentherapie: Organspezifische Komplikationen. , 2021, , 431-451.		Ο
501	Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: aÂprospective multicenter study. Journal of Contemporary Brachytherapy, 2021, 13, 1-11.	0.9	2
502	Dynamic Changes of Generic Quality of Life after Different Treatments for Localized Prostate Cancer. Journal of Clinical Medicine, 2021, 10, 158.	2.4	4
503	The Management of Prostate Cancer. Practical Guides in Radiation Oncology, 2021, , 3-23.	0.1	0
504	Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. World Journal of Urology, 2021, 39, 3259-3264.	2.2	5
505	MicroRNAs and Natural Compounds Mediated Regulation of TGF Signaling in Prostate Cancer. Frontiers in Pharmacology, 2020, 11, 613464.	3.5	6
506	An Assessment of Comparative Marginal Costs to Non-Robotic Surgery for Radical Prostatectomy amongst Public Patients. Journal of Service Science and Management, 2021, 14, 399-411.	0.5	0
507	Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy. International Urology and Nephrology, 2021, 53, 1297-1303.	1.4	12
508	Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors for prostate cancer progression using primary care data. BMJ Open, 2021, 11, e044420.	1.9	8
509	Role of primary care in the management of prostate cancer. The Prescriber, 2021, 32, 11-17.	0.3	2
510	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. BMC Urology, 2021, 21, 18.	1.4	3

#	Article	IF	CITATIONS
511	Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncology, The, 2021, 22, 235-245.	10.7	88
512	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	30.5	434
513	Photoselective Vaporization of the Prostate in the Management of Lower Urinary Tract Symptoms in Prostate Cancer Patients on Active Surveillance. Urology, 2021, 156, 225-230.	1.0	1
514	Morbidity and All-Cause Mortality Following Radical Prostatectomy Compared with Observation for Localized Prostate Cancer in Chinese Men: A Non-Randomized Retrospective Study. Medical Science Monitor, 2021, 27, e928596.	1.1	0
515	Pain Interference and Decreased Physical Function After Emergency General Surgery: Measuring Patientâ€Reported Outcomes. World Journal of Surgery, 2021, 45, 1725-1733.	1.6	3
516	Patient Satisfaction and Regret After Robot-assisted Radical Prostatectomy: A Decision Regret Analysis. Urology, 2021, 149, 122-128.	1.0	17
517	Is Retzius-sparing robot-assisted laparoscopic radical prostatectomy effective in early continence? A single-center experience of the first 50 patients. Turkish Journal of Urology, 2021, 47, 25-130.	1.3	1
518	Experiences of Support for Sexual Dysfunction in Men with Prostate Cancer: Findings from a U.KWide Mixed Methods Study. Journal of Sexual Medicine, 2021, 18, 515-525.	0.6	4
519	Strategies to Minimize Late Effects From Pelvic Radiotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 158-168.	3.8	6
520	Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function. British Journal of Radiology, 2021, 94, 20200433.	2.2	13
521	Evaluation of Patient- and Surgeon-Specific Variations in Patient-Reported Urinary Outcomes 3 Months After Radical Prostatectomy From a Statewide Improvement Collaborative. JAMA Surgery, 2021, 156, e206359.	4.3	13
522	Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma. Cancers, 2021, 13, 1517.	3.7	7
523	Patient-reported Health Status, Comorbidity Burden, and Prostate Cancer Treatment. Urology, 2021, 149, 103-109.	1.0	2
524	Localized and Locally Advanced Prostate Cancer: Treatment Options. Oncology, 2021, 99, 1-9.	1.9	12
525	Patterns of care for men with prostate cancer: the 45 and Up Study. Medical Journal of Australia, 2021, 214, 271-278.	1.7	17
526	Predictors of pathologically aggressive prostate cancer and surgical management. AME Medical Journal, O, 6, 7-7.	0.4	1
527	Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database. The Lancet Digital Health, 2021, 3, e158-e165.	12.3	56
528	Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. PLoS ONE, 2021, 16, e0249123.	2.5	4

#	Article	IF	CITATIONS
529	Effect of Kegel exercises on the prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy. European Journal of Oncology Nursing, 2021, 51, 101913.	2.1	12
530	Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clinical Neurology and Neurosurgery, 2021, 203, 106565.	1.4	42
531	Identifying classes of the pain, fatigue, and depression symptom cluster in long-term prostate cancer survivors—results from the multi-regional Prostate Cancer Survivorship Study in Switzerland (PROCAS). Supportive Care in Cancer, 2021, 29, 6259-6269.	2.2	9
532	Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy. Nature Reviews Urology, 2021, 18, 259-281.	3.8	29
533	Transvesical Versus Posterior Approach to Retzius-Sparing Robot-Assisted Radical Prostatectomy: A Retrospective Comparison With a 12-Month Follow-Up. Frontiers in Oncology, 2021, 11, 641887.	2.8	12
534	Is it Worth Starting Sexual Rehabilitation Before Radical Prostatectomy? Results From a Systematic Review of the Literature. Frontiers in Surgery, 2021, 8, 648345.	1.4	18
536	Single dose prostate radiotherapy — a step too far?. Nature Reviews Urology, 2021, 18, 445-446.	3.8	1
537	Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 1041-1047.	3.9	13
538	Individual risk prediction of urinary incontinence after prostatectomy and impact on treatment choice in patients with localized prostate cancer. Neurourology and Urodynamics, 2021, 40, 1550-1558.	1.5	7
539	Comparative effectiveness of robotic and open radical prostatectomy. Translational Andrology and Urology, 2021, 10, 2158-2170.	1.4	3
540	Management of Lower Urinary Tract Symptoms after Prostate Radiation. Current Urology Reports, 2021, 22, 37.	2.2	4
541	Time pressure predicts decisional regret in men with localized prostate cancer: data from a longitudinal multicenter study. World Journal of Urology, 2021, 39, 3755-3761.	2.2	5
542	Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost–Utility Study. Cancers, 2021, 13, 2687.	3.7	1
543	An integrated multicomponent care model for men affected by prostate cancer: A feasibility study of TrueNTH Australia. Psycho-Oncology, 2021, 30, 1544-1554.	2.3	6
544	Head to head randomized trial of two decision aids for prostate cancer. BMC Medical Informatics and Decision Making, 2021, 21, 154.	3.0	4
545	Turkish Validity and Reliability of Adult Life Quality Scale in Cancer Survivors. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, 2022, 17, 84-93.	0.4	1
546	Radical Prostatectomy: Sequelae in the Course of Time. Frontiers in Surgery, 2021, 8, 684088.	1.4	4
547	External beam radiation therapy carries lower risk of sexual dysfunction as compared to radical prostatectomy in treatment of patients with localized prostate cancer. Clinical Research in Practice the Journal of Team Hippocrates, 2021, 7, .	0.1	0

	CIAIO	CHATION REPORT		
#	Article	IF	CITATIONS	
548	Decision Making in Older Adults With Cancer. Journal of Clinical Oncology, 2021, 39, 2164-2174.	1.6	51	
549	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer and Prostatic Diseases, 2021, 24, 1120-1128.	3.9	10	
550	Oncological and functional outcome after partial prostate HIFU ablation with Focal-One®: a prospective single-center study. Prostate Cancer and Prostatic Diseases, 2021, 24, 1189-1197.	3.9	13	
551	Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. BMC Cancer, 2021, 21, 538.	2.6	29	
552	Predictive Factors of De Novo Overactive Bladder After Radical Prostatectomy in Patients With Clinically Localized Prostate Cancer: A Prospective Observational Study. The Korean Journal of Urological Oncology, 2021, 19, 109-116.	0.1	1	
553	Patientâ€reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial. Cancer Medicine, 2021, 10, 3240-3248.	2.8	3	
554	Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer. JAMA Oncology, 2021, 7, 700.	7.1	40	
555	High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1-10.	0.8	60	
556	Reassessment of Prostate Biopsy Specimens for Patients Referred for Robot-assisted Radical Prostatectomy Rarely Influences Surgical Planning. European Urology Open Science, 2021, 28, 36-42.	0.4	2	
557	Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial. International Journal of Radiation Oncology Biology Physics, 2021, 110, 596-608.	0.8	15	
558	Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy. Cancers, 2021, 13, 3243.	3.7	2	
559	Development of a Management Algorithm for Acute and Chronic Radiation Urethritis and Cystitis. Urologia Internationalis, 2022, 106, 63-74.	1.3	8	
560	Development and Validation of an Interpretable Artificial Intelligence Model to Predict 10-Year Prostate Cancer Mortality. Cancers, 2021, 13, 3064.	3.7	8	
561	The Magnificent MASTER Trial: A Randomised Controlled Trial of Surgery After Postprostatectomy Incontinence. European Urology, 2021, 79, 824-825.	1.9	0	
562	Vigilancia activa del cáncer de próstata. EMC - UrologÃa, 2021, 53, 1-8.	0.0	0	
563	Does Perceived Loneliness Matter for Diverse Older Men and Their Prostate-Specific Antigen Testing Behaviors?. Social Work Research, 2021, 45, 117-128.	0.6	0	
564	Active surveillance for prostate cancer. Translational Andrology and Urology, 2021, 10, 2809-2819.	1.4	16	
565	Data-driven Focal Therapy for Localized Prostate Cancer: A Wake-up Call. European Urology Oncology, 2021, 4, 424-425.	5.4	1	

		15	C
#	ARTICLE	IF	CITATIONS
566	Prostate Cancer Screening in Brazil: a single center experience in the public health system. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 558-565.	1.5	6
567	A Review of PROM Implementation in Surgical Practice. Annals of Surgery, 2022, 275, 85-90.	4.2	16
568	Every urologist and oncologist should know about treating sexual and gender minority prostate cancer patients: translating research findings into clinical practice. Translational Andrology and Urology, 2021, 10, 3208-3225.	1.4	18
569	Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study. Radiology and Oncology, 2021, 55, 474-481.	1.7	1
570	Development of otology specific outcome measure: Ear Outcome Survey-16 (EOS-16). Journal of Otology, 2021, 16, 150-157.	1.0	3
571	Insurance Approval for Definitive Proton Therapy for Prostate Cancer. International Journal of Particle Therapy, 2022, 8, 36-42.	1.8	3
572	Can patients with lowâ€risk prostate cancer really benefit from radical treatment?: A systematic review and network metaâ€analysis. Andrologia, 2021, 53, e14122.	2.1	1
573	Post-Treatment Adverse Health Correlates among Prostate Cancer Survivors in a Sample of Men Residing in Atlantic Canada. Current Oncology, 2021, 28, 2812-2822.	2.2	8
574	Comparative Effectiveness Research in Localized Prostate Cancer: A 10-Year Follow-up Cohort Study. International Journal of Radiation Oncology Biology Physics, 2021, 110, 718-726.	0.8	7
575	Radiation therapyâ€ a ssociated toxicity: Etiology, management, and prevention. Ca-A Cancer Journal for Clinicians, 2021, 71, 437-454.	329.8	129
576	Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate—FACT-P (Version 4) in Prostate Cancer Patients. Journal of Cancer Education, 2021, , 1.	1.3	0
577	Quality of Life After Prostate Cancer Treatment. International Journal of Radiation Oncology Biology Physics, 2021, 110, 727-730.	0.8	3
579	Prospective Longitudinal Health-related Quality of Life Analysis of the Finnish Arm of the PRIAS Active Surveillance Cohort: 11 Years of Follow-up. European Urology Focus, 2022, 8, 1151-1156.	3.1	2
580	Efficacy, Use, and Acceptability of a Web-Based Self-management Intervention Designed to Maximize Sexual Well-being in Men Living With Prostate Cancer: Single-Arm Experimental Study. Journal of Medical Internet Research, 2021, 23, e21502.	4.3	3
581	Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. Cancers, 2021, 13, 4251.	3.7	17
582	Salvage therapy for prostate cancer after radical prostatectomy. Nature Reviews Urology, 2021, 18, 643-668.	3.8	26
583	High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial. Applied Physiology, Nutrition and Metabolism, 2021, 46, 1535-1544.	1.9	11
584	Sildenafil Citrate and Risk of Biochemical Recurrence in Prostate Cancer Patients Treated with Radiation Therapy: Post-Hoc Analysis of a Randomized Controlled Trial. Journal of Sexual Medicine, 2021, 18, 1467-1472.	0.6	4

#	Article	IF	Citations
585	An online Sexual Health and Rehabilitation eClinic (TrueNTH SHAReClinic) for prostate cancer patients: a feasibility study. Supportive Care in Cancer, 2022, 30, 1253-1260.	2.2	4
586	Costâ€effectiveness analysis of hydrogel spacer for rectal toxicity reduction in prostate external beam radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 931-939.	1.8	2
587	Practical considerations for prostate hypofractionation in the developing world. Nature Reviews Urology, 2021, 18, 669-685.	3.8	20
588	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation. Clinical and Translational Science, 2021, 14, 2314-2326.	3.1	4
589	Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model andÂClinical Translation. Journal of Vascular and Interventional Radiology, 2021, 32, 1103-1112.e12.	0.5	11
590	Incremental modification of robotic prostatectomy technique can lead to aggregated marginal gains to significantly improve functional outcomes without compromising oncological control. Journal of Robotic Surgery, 2021, , 1.	1.8	4
591	PSA: Declining utilization of prostate brachytherapy. Brachytherapy, 2021, , .	0.5	5
592	Patient-Reported Outcomes Integrated Within an Electronic Medical Record in Patients With Head and Neck Cancer. JCO Clinical Cancer Informatics, 2021, 5, 842-848.	2.1	4
593	Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5Âyr in the CHHiP trial (CRUK/06/016). European Urology Oncology, 2021, 4, 980-992.	5.4	14
594	Erectile Function Post Prostate Biopsy: A Systematic Review and Meta-analysis. Urology, 2021, 155, 1-8.	1.0	4
595	Therapeutic Effect of Magnetic Stimulation Therapy on Pelvic Floor Muscle Dysfunction. , 0, , .		1
596	Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer. Radiation Oncology Journal, 2021, 39, 231-238.	1.5	6
597	Focal Therapy Is a Viable Treatment for Low-Risk Prostate Cancer. Journal of Endourology, 2021, 35, 1281-1283.	2.1	3
598	The unique information and communication needs of men affected by prostate cancer: A qualitative study of men's experience. European Journal of Cancer Care, 2021, 30, e13503.	1.5	5
599	Evaluation of Benefits and Harms of Surgical Treatments for Post–radical Prostatectomy Urinary Incontinence: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 1042-1052.	3.1	8
600	Effects of Biofeedback Combined With Pilates Training on Post-prostatectomy Incontinence. Urology, 2021, 155, 152-159.	1.0	8
601	Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys. Value in Health, 2021, 24, 1676-1685.	0.3	0
602	Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis. Value in Health, 2022, 25, 133-146.	0.3	8

#	Article	IF	Citations
603	Illness representations, coping and anxiety among men withÂlocalized prostate cancer over an 18â€months period: AÂparallel vs. levelâ€contrast mediation approach. Psycho-Oncology, 2021, , .	2.3	1
604	Clinical use of expanded prostate cancer index composite-based health-related quality of life outcomes after robot-assisted radical prostatectomy for localized prostate cancer. Prostate International, 2021, 10, 62-67.	2.3	3
605	The Impact of Burn Survivor Preinjury Income and Payer Status on Health-Related Quality of Life. Journal of Burn Care and Research, 2022, 43, 293-299.	0.4	2
606	Radiotherapy or Surgery? Comparative, Qualitative Assessment of Online Patient Education Materials on Prostate Cancer. Current Oncology, 2021, 28, 3420-3429.	2.2	9
607	Stratification of Potency Outcomes Following Robot-Assisted Laparoscopic Radical Prostatectomy Based on Age, Preoperative Potency, and Nerve Sparing. Journal of Endourology, 2021, 35, 1631-1638.	2.1	18
608	Prostate cancer. Lancet, The, 2021, 398, 1075-1090.	13.7	240
609	High intensity focused ultrasound ablation for prostate cancer: whole versus partial gland ablation. Clinical Genitourinary Cancer, 2021, , .	1.9	5
610	Dissecting the role of radical cystectomy and urinary diversion in post-operative complications: an analysis using the American College of Surgeons national surgical quality improvement program database. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 1006-1019.	1.5	4
611	Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer. Clinical and Translational Radiation Oncology, 2021, 31, 34-41.	1.7	4
612	Patient Reported Quality of Life Outcomes After Definitive Radiation Therapy With Absorbable Spacer Hydrogel for Prostate Cancer. Advances in Radiation Oncology, 2021, 6, 100755.	1.2	1
613	Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil. Value in Health Regional Issues, 2021, 26, 89-97.	1.2	1
614	Health Literacy and Patient -Reported Outcomes. , 2022, , 203-217.		0
615	A glycan-based plasmonic sensor for prostate cancer diagnosis. Analyst, The, 2021, 146, 6852-6860.	3.5	2
616	Conventional and Moderately Hypofractionated Radiation Therapy for Prostate Cancer. Practical Guides in Radiation Oncology, 2021, , 91-104.	0.1	0
617	Sexual function and rehabilitation after radiation therapy for prostate cancer: a review. International Journal of Impotence Research, 2021, 33, 410-417.	1.8	7
618	National Survey of Endocrinologists and Surgeons Regarding Active Surveillance for Low-Risk Papillary Thyroid Cancer. Endocrine Practice, 2021, 27, 1-7.	2.1	19
619	A 10% Tomato Diet Selectively Reduces Radiation-Induced Damage in TRAMP Mice. Journal of Nutrition, 2021, 151, 3421-3430.	2.9	2
620	High Dose Rate Prostate Brachytherapy. Practical Guides in Radiation Oncology, 2021, , 127-151.	0.1	Ο

#	Article	IF	CITATIONS
621	Update and optimization of active surveillance in prostate cancer in 2021. Actas Urológicas Españolas (English Edition), 2021, 45, 1-7.	0.2	1
622	Introduction for sexuality after prostate cancer. International Journal of Impotence Research, 2021, 33, 389-390.	1.8	2
623	Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy. Asian Journal of Andrology, 2021, 23, 370.	1.6	1
624	Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. Cancer Causes and Control, 2021, 32, 261-269.	1.8	8
625	Symptom trajectories and influencing factors of prostate cancer following radical prostatectomy in Chinese patients. Annals of Palliative Medicine, 2021, 10, 7747-7758.	1.2	2
626	Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomy. Asian Journal of Andrology, 2021, 23, 520.	1.6	2
627	Quality of Life After Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: 5-Year Results. International Journal of Radiation Oncology Biology Physics, 2017, 99, 374-377.	0.8	34
628	A systematic review of home-based dietary interventions during radiation therapy for cancer. Technical Innovations and Patient Support in Radiation Oncology, 2020, 16, 10-16.	1.9	3
629	Role of Multiparametric Magnetic Resonance Imaging Prostate Specific Antigen Density and PI-RADSâ,,¢ Score in Predicting Up Staging in Men on Active Surveillance. Urology Practice, 2019, 6, 117-122.	0.5	2
631	Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 898-904.	1.3	10
632	Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. Journal of Urology, 2019, 202, 936-943.	0.4	14
633	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. BMJ Open, 2017, 7, e017729.	1.9	27
634	Evaluation of benefits and harms of surgical treatments for post-radical prostatectomy urinary incontinence: a systematic review and meta-analysis protocol. F1000Research, 2019, 8, 1155.	1.6	3
635	The impact of combining human and online supportive resources for prostate cancer patients. Journal of Community and Supportive Oncology, 2017, 15, e321-e329.	0.1	8
636	Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial. American Journal of Gastroenterology, 2021, 116, 152-161.	0.4	34
637	Super active surveillance for low-risk prostate cancer Opinion: Yes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 210-214.	1.5	3
638	Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: a systematic review and meta-analysis. Oncotarget, 2017, 8, 99057-99065.	1.8	11
639	The Tablet-Based, Engagement, Assessment, Support, and Sign-Posting (EASSi) Tool for Facilitating and Structuring Sexual Well-Being Conversations in Routine Prostate Cancer Care: Mixed-Methods Study. JMIR Cancer, 2020, 6, e20137.	2.4	3

#	Article	IF	CITATIONS
640	A Web-Based Intervention to Reduce Distress After Prostate Cancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings. JMIR Cancer, 2018, 4, e8.	2.4	11
641	Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the) Tj ETQq1 1 (2020.72.595-604.).784314 r	gBT/Overloo
642	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. Health Technology Assessment, 2018, 22, 1-96.	2.8	33
643	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	2.8	22
644	Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction: the UNBLOCS RCT. Health Technology Assessment, 2020, 24, 1-96.	2.8	6
645	Focal Ablation of Prostate Cancer. Reviews in Urology, 2018, 20, 145-157.	0.9	7
646	Erectile dysfunction in prostate cancer patients treated with intensity-modulated radiation therapy. Indian Journal of Cancer, 2020, 57, 70.	0.2	4
647	A structured framework for optimizing high-intensity focused ultrasound ablative treatment in localized prostate cancer. Investigative and Clinical Urology, 2019, 60, 312.	2.0	4
648	Extracting Patient-Centered Outcomes from Clinical Notes in Electronic Health Records: Assessment of Urinary Incontinence After Radical Prostatectomy. EGEMS (Washington, DC), 2019, 7, 43.	2.0	8
649	Prostate Cancer: Locoregional Disease. UNIPA Springer Series, 2021, , 791-803.	0.1	0
650	Guidelines for radiotherapy of prostate cancer (2020 edition). Precision Radiation Oncology, 2021, 5, 160-182.	1.1	8
651	Sexual rehabilitation recommendations for prostate cancer survivors and their partners from a biopsychosocial Prostate Cancer Supportive Care Program. Supportive Care in Cancer, 2022, 30, 1853-1861.	2.2	3
652	Characterization of an Iodinated Rectal Spacer for Prostate Photon and Proton Radiation Therapy. Practical Radiation Oncology, 2022, 12, 135-144.	2.1	7
653	Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition. European Urology, 2022, 81, 305-312.	1.9	6
654	Development of new comorbidities in patients awaiting urinary incontinence surgery following radical prostatectomy. Urology, 2021, , .	1.0	0
656	Focal Cryotherapy. Current Clinical Urology, 2017, , 283-291.	0.0	0
658	Re: Behandling eller aktiv monitorering ved prostatakreft?. Tidsskrift for Den Norske Laegeforening, 2017, 137, 259-260.	0.2	0
659	Ethical and Legal Considerations in Active Surveillance for Prostate Cancer. Current Clinical Urology, 2018, , 31-39.	0.0	0

#	Article	IF	CITATIONS
660	Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study. BMJ Open, 2017, 7, e017372.	1.9	0
661	Outcomes of Active Surveillance in Localized Prostate Cancer. The Korean Journal of Urological Oncology, 2017, 15, 93-102.	0.1	0
662	Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What's New and What's Not. European Urology, 2017, 72, 886-887.	1.9	5
663	Health Literacy and Patient -Reported Outcomes. Advances in Medical Technologies and Clinical Practice Book Series, 2018, , 109-123.	0.3	2
665	RASTREIO DO CÃ,NCER DE PRÓSTATA: REVISÃ∱O SISTEMÃTICA DA LITERATURA SOBRE AS PERSPECTIVAS MUNDIAIS. Revista De Atenção à Saúde, 2018, 16, .	0.1	0
666	The problem of early continence recovery after radical prostatectomy. Onkourologiya, 2018, 13, 70-78.	0.3	1
667	Prostatakarzinom. , 2018, , 305-368.		0
668	Outcomes Following Various Treatment Options for Clinically Localized Prostate Cancer. The Korean Journal of Urological Oncology, 2018, 16, 7-14.	0.1	0
669	Overview of Toxicity Outcomes with Prostate SBRT and Comparison to Other Treatment Interventions (Urinary, Rectal and Sexual Outcomes). , 2019, , 111-127.		0
670	Quality of Life Outcomes After SBRT. , 2019, , 129-139.		0
671	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
672	Prostatakarzinom. , 2019, , 137-159.		0
673	The Treatments for Low-Risk Prostate Cancer. The Korean Journal of Urological Oncology, 2019, 17, 7-21.	0.1	0
674	Pigments from Filamentous Ascomycetes for Combination Therapy. Current Medicinal Chemistry, 2019, 26, 3812-3834.	2.4	0
675	Surgical Treatment of Male Stress Urinary Incontinence: An Overview. , 2020, , 805-809.		0
676	Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer. Journal of Contemporary Brachytherapy, 2020, 12, 540-546.	0.9	8
679	Quality of life evaluation of patients after radical treatment of prostate cancer. Proceedings of the National Academy of Sciences of Belarus, Medical Series, 2020, 17, 275-286.	0.1	0
681	Have urinary function outcomes after radical prostatectomy improved over the past decade?. Cancer, 2022, 128, 1066-1073.	4.1	3

#	ARTICLE Wie soll ich mich entscheiden? Und was bedeutet das für mich?. , 2020, , 121-129.	IF	Citations
683	Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer. Radiology and Oncology, 2020, 55, 88-96.	1.7	2
684	Toxicity Management for Pelvic Tumors in Radiation Oncology. , 2020, , 231-266.		0
686	Environmental Enrichment in Postoperative Pain and Surgical Care. Annals of Surgery, 2021, 273, 86-95.	4.2	12
687	Selection of patients for nerve sparing surgery in robotâ€essisted radical prostatectomy. BJUI Compass, 2022, 3, 6-18.	1.3	9
688	Focal Therapy for Prostate Cancer: Getting Ready for Prime Time. European Urology, 2022, 81, 34-36.	1.9	11
689	Identification of Risk Loci for Radiotoxicity in Prostate Cancer by Comprehensive Genotyping of TGFB1 and TGFBR1. Cancers, 2021, 13, 5585.	3.7	0
690	Predictors for the utilization of social service counseling by prostate cancer patients. Supportive Care in Cancer, 2021, , 1.	2.2	1
692	Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. Cancers, 2020, 12, 2804.	3.7	8
693	Radiation Therapy for Prostate Cancer. Missouri Medicine, 2018, 115, 146-150.	0.3	7
694	High-Intensity-Focused Ultrasound for Prostate Cancer. , 2021, , 197-213.		0
695	A Review of High-Intensity Focused Ultrasound in Urology. Cancers, 2021, 13, 5696.	3.7	8
696	Health-Related Quality of Life following Cytoreductive Radical Prostatectomy in Patients with De-Novo Oligometastatic Prostate Cancer. Cancers, 2021, 13, 5636.	3.7	9
697	An Adaptation, Extension and Pre-Testing of an Interactive Decision Aid for Men Diagnosed with Localized Prostate Cancer in Iceland: A Mixed-Method Study. Behavioral Medicine, 2023, 49, 137-150.	1.9	0
699	Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1–2b Study). European Urology, 2022, 81, 396-406.	1.9	11
700	Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. International Journal of Radiation Oncology Biology Physics, 2022, 112, 83-92.	0.8	6
701	Hospital readmissions for patients with prostate cancer are higher after radiotherapy than after prostatectomy. Investigative and Clinical Urology, 2022, 63, 34.	2.0	1
702	Patient Decision-Making Factors in Aggressive Treatment of Low-Risk Prostate Cancer. JNCI Cancer Spectrum, 2022, 6, .	2.9	1

#	Article	IF	CITATIONS
703	Prostatakarzinom: Strahlentherapie als kurative Option. , 0, , .		0
704	A â€~real-world' standard for radical prostatectomy: Analysis of the British Association of Urological Surgeons Complex Operations Reports, 2016–2018. Journal of Clinical Urology, 0, , 205141582110639.	0.1	Ο
705	A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 75, 1762-1775.	1.1	7
706	Two-year quality of life after robot-assisted radical prostatectomy according to pentafecta criteria and cancer of the prostate risk assessment (CAPRA-S). Scientific Reports, 2022, 12, 244.	3.3	5
707	Assessing Inter-Fraction Changes in The Size and Position of The Penile Bulb During Daily MR-Guided Radiation Therapy to The Prostate Bed: Do We Need to Adjust How We Plan Radiation in The Post-Radical Prostatectomy Setting to Reduce Risk of Erectile Dysfunction?. Clinical Genitourinary Cancer, 2022, , .	1.9	1
708	Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer. Cancers, 2022, 14, 517.	3.7	2
709	FACE Value of Patient-Reported Outcomes in Dose-Escalated Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 93-95.	0.8	0
710	eSyM: An Electronic Health Record–Integrated Patient-Reported Outcomes–Based Cancer Symptom Management Program Used by Six Diverse Health Systems. JCO Clinical Cancer Informatics, 2022, 6, e2100137.	2.1	19
711	Creation and Psychometric Validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients-The Restore-2 Study. Journal of Sexual Medicine, 2022, 19, 529-540.	0.6	7
712	Development of a Sexual Quality of Life Questionnaire for Men-Who-Have-Sex-With-Men With Prostate Cancer. Sexual Medicine, 2022, 10, 100480-100480.	1.6	6
713	Impacto de la prostatectomÃa radical y la radioterapia en la calidad de vida de pacientes con cáncer de próstata clÃnicamente localizado. Revista Mexicana De Urologia, 2021, 81, 1-14.	0.0	0
714	Predicting toxicity caused by high-dose-rate brachytherapy single boost for prostate cancer. Journal of Contemporary Brachytherapy, 2022, 14, 7-14.	0.9	Ο
715	New TRPM8 Blockers Exert Anticancer Activity Over Castration-Resistant Prostate Cancer Models. SSRN Electronic Journal, 0, , .	0.4	0
716	Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers. Cancers, 2022, 14, 1004.	3.7	3
717	The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis. Arab Journal of Urology Arab Association of Urology, 2022, 20, 1-10.	1.5	0
718	Focal therapy: definition and rationale. Current Opinion in Urology, 2022, 32, 218-223.	1.8	0
719	Development of a 3D CNN-based Al Model for Automated Segmentation of the Prostatic Urethra. Academic Radiology, 2022, 29, 1404-1412.	2.5	9
720	Robotic-assisted Versus Laparoscopic Radical Prostatectomy: 12-month Outcomes of the Multicentre Randomised Controlled LAP-01 Trial. European Urology Focus, 2022, 8, 1583-1590.	3.1	14

#	Article	IF	CITATIONS
721	Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN. Future Oncology, 2022, , .	2.4	0
722	Management of prostate cancer in older patients. Japanese Journal of Clinical Oncology, 2022, 52, 513-525.	1.3	5
723	Five-year follow-up study of a population-based prospective cohort of men with low-risk prostate cancer: the treatment options in prostate cancer study (TOPCS): study protocol. BMJ Open, 2022, 12, e056675.	1.9	0
724	Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. European Urology, 2022, 81, 503-514.	1.9	13
725	Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. Nature Reviews Urology, 2022, 19, 263-279.	3.8	5
726	Quality of life after roboticâ€assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAPâ€01). Prostate, 2022, 82, 894-903.	2.3	2
727	Experience Measures after Radical Prostatectomy: A Register-Based Study Evaluating the Association between Patient-Reported Symptoms and Quality of Information. Healthcare (Switzerland), 2022, 10, 519.	2.0	1
728	The dosimetric advantages of perirectal hydrogel spacer in men with localized prostate cancer undergoing stereotactic ablative radiotherapy (SABR). Medical Dosimetry, 2022, 47, 173-176.	0.9	2
729	Female erectile tissues and sexual dysfunction after pelvic radiotherapy: A scoping review. Ca-A Cancer Journal for Clinicians, 2022, 72, 353-359.	329.8	8
730	Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. Minerva Urology and Nephrology, 2022, 74, .	2.5	5
731	Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer. Frontiers in Oncology, 2022, 12, 860848.	2.8	3
732	Feasibility of magnetic resonance imagingâ€ultrasound guided highâ€doseâ€rate brachytherapy for localized prostate cancer: Preliminary results from a prospective study. International Journal of Urology, 2022, , .	1.0	0
733	A Pilot Feasibility Study of Digital Health Coaching for Men With Prostate Cancer. JCO Oncology Practice, 2022, 18, e1132-e1140.	2.9	1
734	Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing) Tj ETQq1 1 0.7	′84314 rgi 2.5	BT /Qverlock
735	Editorial: Sequelae of Prostate Cancer Therapy: Avoidance Strategies and Management Options. Frontiers in Surgery, 2022, 9, 849669.	1.4	0
736	Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot Study. European Urology Open Science, 2022, 39, 48-54.	0.4	5
737	Quality-of-life and toxicity in cancer patients treated with multiple courses of radiation therapy. Clinical and Translational Radiation Oncology, 2022, 34, 23-29.	1.7	6
738	Patient Education for Radical Prostatectomy: Development of a Program Tailored to the Needs of Prostate Cancer Patients. American Journal of Men's Health, 2021, 15, 155798832110633.	1.6	0

#	Article	IF	CITATIONS
739	A Model-Based Framework to Identify Optimal Administration Protocols for Immunotherapies in Castration-Resistance Prostate Cancer. Cancers, 2022, 14, 135.	3.7	2
740	Current androgen receptor antagonists under investigation for resistant prostate cancer. Expert Review of Anticancer Therapy, 2022, 22, 191-202.	2.4	5
741	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives. Cancers, 2022, 14, 147.	3.7	2
742	Microwave focal therapy of prostate cancer: a nonâ€clinical study and exploratory clinical trial. BJU International, 2022, 130, 776-785.	2.5	4
749	No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance. Scientific Reports, 2022, 12, 6743.	3.3	4
750	Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 190-195.	1.3	2
751	The effects of pharmacist interventions on health outcomes in patients with advanced prostate cancer in Brazil. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
752	Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer. Cancers, 2022, 14, 2226.	3.7	4
753	Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). European Urology Focus, 2022, 8, 1607-1616.	3.1	1
754	New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models. European Journal of Medicinal Chemistry, 2022, 238, 114435.	5.5	8
755	Retzius-Sparing <i>vs</i> Modified Anatomical Structure Preserving and Retzius-Repairing Robotic-Assisted Radical Prostatectomy: A Prospective Randomized Comparison on Functional Outcomes with a 1-Year Follow-Up. Journal of Endourology, 2022, 36, 1214-1222.	2.1	4
756	Acute, Subchronic, and Chronic Complications of Radical Prostatectomy Versus Radiotherapy With Hormone Therapy in Older Adults With High-Risk Prostate Adenocarcinoma. Frontiers in Oncology, 2022, 12, 875036.	2.8	1
757	A comparative study of patient-reported outcomes after contemporary radiation techniques for prostate cancer. Radiotherapy and Oncology, 2022, 171, 164-172.	0.6	1
758	Effectiveness of cognitive behavioral therapy in improving functional health in cancer survivors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 175, 103709.	4.4	11
760	Relative Incidence of Emergency Department Visits After Treatment for Prostate Cancer with Radiation Therapy or Radical Prostatectomy. Practical Radiation Oncology, 2022, , .	2.1	0
761	Evaluating post radical prostatectomy mechanisms of early continence. Prostate, 2022, 82, 1186-1195.	2.3	10
762	An update on the current status and future prospects of erectile dysfunction following radical prostatectomy. Prostate, 2022, 82, 1135-1161.	2.3	4
763	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0

		CITATION RE	PORT	
#	Article		IF	CITATIONS
764	Patient reported outcomes and health related quality of life in localized prostate cancer: A current evidence. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 304		1.6	3
766	Real-life daily activity: the impact of misbeliefs on quality of life among cancer patients. ES 2022, 7, 100498.	MO Open,	4.5	1
767	Robot-Assisted Surgery vs Robotic Stereotactic Body Radiotherapy in Prostate Cancer: A C Analysis. Frontiers in Oncology, 0, 12, .	cost-Utility	2.8	2
768	Current Status and Future Perspective on the Management of Lymph Node-Positive Prosta after Radical Prostatectomy. Cancers, 2022, 14, 2696.	ate Cancer	3.7	6
769	Patient Reported Outcomes for Quality of Life (QOL) By Expanded Prostate Cancer Index Average 15 Years Post Treatment. Clinical and Translational Radiation Oncology, 2022, , .	(EPIC) on	1.7	3
770	Biomarkers for prostate cancer detection and risk stratification. Therapeutic Advances in U 2022, 14, 175628722211039.	Jrology,	2.0	21
771	Prostate cancer: understanding patients' treatment options. Nursing Standard (Royal	College of) Tj ETQq0 0	0 rgBT /Ov	verlock 10 T
772	The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Ol- with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort Study. Journal of C Medicine, 2022, 11, 3451.	d Adults linical	2.4	2
773	PSA: role in screening and monitoring patients with prostate cancer. , 2022, , 131-172.			2
774	Sexual Function of Men Undergoing Active Prostate Cancer Treatment Versus Active Surv Results of the Europa Uomo Patient Reported Outcome Study. Touch Reviews in Oncolog Haematology, 2022, 18, 88.	eillance: y &	0.2	0
775	Long-term functional outcomes of vesicourethral anastomosis with bladder neck preserva distal urethral length preservation after videolaparoscopic radical prostatectomy. Wideocl Inne Techniki Maloinwazyjne, 0, , .	tion and hirurgia l	0.7	1
776	Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prosta BJU International, 2023, 131, 280-287.	ce cancer.	2.5	9
777	Current status of routine use of Patient-Reported Outcome in the tertiary hospital clinical Republic of Korea. Korean Journal of Clinical Pharmacy, 2022, 32, 74-83.	setting in	0.3	0
778	Cross-cultural differences in men on active surveillance' anxiety: a longitudinal compa Italian and Dutch patients from the Prostate cancer Research International Active Surveilla BMC Urology, 2022, 22, .		1.4	0
779	Four-year quality-of-life outcomes in low- to intermediate-risk prostate cancer patients foll definitive stereotactic body radiotherapy versus management with active surveillance. We of Urology, 2022, 40, 2213-2219.		2.2	1
780	Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study patients with prostate cancer. Journal of Clinical Pathology, 2023, 76, 690-697.	in 30 509	2.0	2
781	Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Ca PSA are Not Predictive of Residual or Recurrent Disease. Urologic Oncology: Seminars and Investigations, 2022, 40, 451.e15-451.e20.		1.6	7
783	Redesign of Perioperative Care Pathways. , 2023, , 185-192.			0

#	Article	IF	CITATIONS
784	A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.8	2
785	Impact of prostate biopsy technique on outcomes of the precision prostatectomy procedure. BMJ Surgery, Interventions, and Health Technologies, 2022, 4, e000122.	0.9	0
786	The role of prophylactic prostatectomy as a primary prevention strategy in high-risk germline mutation carriers. Current Opinion in Urology, 0, Publish Ahead of Print, .	1.8	1
787	Analysis of the methodology for calculating the dose of external radiation exposure of the population. IOP Conference Series: Earth and Environmental Science, 2022, 1061, 012061.	0.3	0
788	Listening to the Patient Voice Adds Value to Cancer Clinical Trials. Journal of the National Cancer Institute, 2022, 114, 1323-1332.	6.3	10
789	Transperineal Ultrasound Before and After Prostatectomy. Journal of Ultrasound in Medicine, 0, , .	1.7	0
790	Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. Scientific Reports, 2022, 12, .	3.3	5
791	Impact of active surveillance for prostate cancer on the risk of depression and anxiety. Scientific Reports, 2022, 12, .	3.3	3
793	Prostatectomy in Patients with Oligometastatic Hormone-sensitive Prostate Cancer? Not Yet. European Urology Oncology, 2022, 5, 526-527.	5.4	2
794	Prostate cancer–Exercise and Metformin Trial (Pre-EMpT): study protocol for a feasibility factorial randomized controlled trial in men with localised or locally advanced prostate cancer. Pilot and Feasibility Studies, 2022, 8, .	1.2	1
795	Late Adverse Health Outcomes and Quality of Life after curative radiotherapyÂ+Âlong-term ADT in Prostate Cancer Survivors: Comparison with men from the general population. Clinical and Translational Radiation Oncology, 2022, 37, 78-84.	1.7	1
796	Association Between Receipt of Definitive Treatment for Localized Prostate Cancer and Adverse Health Outcomes: A Claims-Based Approach. Value in Health, 2022, , .	0.3	0
797	Enhancing nanoparticle accumulation in two dimensional, three dimensional, and xenograft mouse cancer cell models in the presence of docetaxel. Scientific Reports, 2022, 12, .	3.3	12
798	Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer. European Urology Oncology, 2022, , .	5.4	3
799	Radiotherapy to the Primary Tumor: The First Step of a Tailored Therapy in Metastatic Prostate Cancer. Diagnostics, 2022, 12, 1981.	2.6	4
800	Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology. Frontiers in Oncology, 0, 12, .	2.8	1
801	Cost effectiveness of treatment strategies for high risk prostate cancer. Cancer, 2022, 128, 3815-3823.	4.1	2
802	Tempering optimism for MRI-guided focused ultrasound therapy. Lancet Oncology, The, 2022, 23, e438.	10.7	0

#	Article	IF	CITATIONS
803	Tempering optimism for MRI-guided focused ultrasound therapy – Authors' reply. Lancet Oncology, The, 2022, 23, e439.	10.7	0
804	Advances in Focal Therapy for Men with Low-Intermediate Risk Prostate Cancer. , 2022, , .		Ο
805	Comprehension, utility, and preferences of prostate cancer survivors for visual timelines of patient-reported outcomes co-designed for limited graph literacy: meters and emojis over comics. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 1838-1846.	4.4	6
806	Long-term Health-related Quality of Life in Patients on Active Surveillance for Prostate Cancer: A Systematic Review. European Urology Oncology, 2022, , .	5.4	1
807	Screening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testing. Journal of Medical Screening, 2022, 29, 268-271.	2.3	6
808	Fully automated segmentation of prostatic urethra for MRâ€guided radiation therapy. Medical Physics, 2023, 50, 354-364.	3.0	3
809	Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial. Pharmacoeconomics, 2022, 40, 1207-1220.	3.3	3
810	Modern paradigms for prostate cancer detection and management. Medical Journal of Australia, 2022, 217, 424-433.	1.7	13
811	Unmet Sexual Health Needs of Patients and Female Partners Following Diagnosis and Treatment for Prostate Cancer. Journal of Sexual Medicine, 2022, 19, 1797-1803.	0.6	5
812	Rehabilitation nach Radiotherapie des lokalisierten Prostatakarzinoms. Springer Reference Medizin, 2022, , 1-12.	0.0	0
813	Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk. Biomedicines, 2022, 10, 2446.	3.2	3
814	Patient-Factors Influencing the 2-Year Trajectory of Mental and Physical Health in Prostate Cancer Patients. Current Oncology, 2022, 29, 8244-8260.	2.2	Ο
815	"Targeted microwave ablation: another way to kick the can(cer) down the road?― Prostate Cancer and Prostatic Diseases, 0, , .	3.9	0
816	Surgical Tolerability and Frailty in Elderly Patients Undergoing Robot-Assisted Radical Prostatectomy: A Narrative Review. Cancers, 2022, 14, 5061.	3.7	2
818	Adequacy of sexual care information given to prostate cancer patients receiving radical external beam radiotherapy. Journal of Radiotherapy in Practice, 0, , 1-8.	0.5	0
819	Whole-gland high-intensity focused ultrasound ablation and transurethral resection of the prostate in the patients with prostate cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	2.8	1
820	Pathway for post-prostatectomy urinary incontinence: impact on patient confidence and satisfaction. British Journal of Nursing, 2022, 31, S24-S31.	0.7	3
821	Virtual and Augmented Reality as a Novel Opportunity to Unleash the Power of Radiotherapy in the Digital Era: A Scoping Review. Applied Sciences (Switzerland), 2022, 12, 11308.	2.5	4

ARTICLE IF CITATIONS # French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and 822 0.8 15 management of localised disease. Progres En Urologie, 2022, 32, 1275-1372. Patient-reported functional outcome measures and treatment choice for prostate cancer. BMC 1.4 Urology, 2022, 22, . Impact of Comprehensive Health Insurance on Quality of Life in Low-Income Hispanic Men with 824 1.0 0 Prostate Cancer. Urology, 2022, , . Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused 3.1 Ultrasound: The FOXPRO Trial. European Urology Focus, 2023, 9, 283-290. Patient preferences for treatment modalities for localised prostate cancer. BJUI Compass, 0, , . 826 1.3 0 Variation in patient reported outcomes following radical prostatectomy: A bi-national registry-based study. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 105.e9-105.e18. 1.6 Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications 828 3.1 1 for Active Surveillance. European Urology Focus, 2023, 9, 662-668. Association of baseline self-reported fatigue with overall survival after stereotactic body radiation 829 2.8 therapy for localized prostate cancer. Frontiers in Oncology, 0, 12, . Sexual and urinary function in prostate cancer clinical studies and the Europa Uomo Patient Reported 830 2.5 2 Outcome Study: does it match?. Minerva Urology and Nephrology, 2023, 75, . Undergoing radical treatment for prostate cancer and its impact on wellbeing: A qualitative study 2.5 exploring men's experiences. PLoS ONE, 2022, 17, e0279250. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. Lancet 832 10.7 11 Oncology, The, 2022, 23, e534-e543. Partial gland ablation using high-intensity focused ultrasound versus robot-assisted radical 834 2.3 prostatectomy: a propensity score-matched study. Prostate International, 2022, , . Strahlentherapie bei lokoregionÄren Metastasen. Springer Reference Medizin, 2023, , 1-11. 835 0.0 0 Visual Analogue Scale (VAS) in the Evaluation of Functional Outcomes After Three-dimensional 1.0 Laparoscopic Prostatectomy. Urology, 2023, 172, 121-125. Atualizações sobre a prostatectomia radical para Câncer de próstata localizado. Brazilian Journal of 837 0.1 0 Health Review, 2023, 6, 1184-1201. Protocol for a systematic review and meta-analysis on preoperative risk factors for failure after fixed sling implantation for post-prostatectomy stress urinary incontinence. F1000Research, 0, 12, 19. Tissue distribution of ethanol after intraprostatic injection using a porous needle. Frontiers in 839 2.8 0 Oncology, 0, 12, . <scp>Healthâ€related</scp> quality of life the first year after a prostate cancer diagnosis a systematic 840 review. International Journal of Urological Nursing, 2023, 17, 15-28.

#	Article	IF	CITATIONS
841	Research progress on gels-based nanocomposites in the diagnostics and therapy of prostate diseases. Materials Today Sustainability, 2023, 21, 100323.	4.1	3
842	Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer. JAMA Oncology, 2023, 9, 365.	7.1	83
843	Addressing Gender-Related Inequality in Continence Care. British Journal of Nursing, 2023, 32, 1-16.	0.7	1
844	Prospective Long-term Health-related Quality of Life Outcomes After Surgery, Radiotherapy, or Active Surveillance for Localized Prostate Cancer. European Urology Open Science, 2023, 48, 60-69.	0.4	0
845	Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure. ESMO Open, 2023, 8, 100775.	4.5	1
846	Intraâ€operative fluorescenceâ€based detection of positive surgical margins during radical prostatectomy: Lessons learned from a pilot ex vivo translational study. Lasers in Surgery and Medicine, 0, , .	2.1	0
847	Toward mechatronic MRIâ€guided focal laser ablation of the prostate: Robust registration for improved needle delivery. Medical Physics, 2023, 50, 1259-1273.	3.0	1
848	Global burden of prostate cancer attributable to smoking among males in 204 countries and territories, 1990–2019. BMC Cancer, 2023, 23, .	2.6	5
849	"Urethral-Sparing―Robotic Radical Prostatectomy: Critical Appraisal of the Safety of the Technique Based on the Histologic Characteristics of the Prostatic Urethra. Current Oncology, 2023, 30, 1065-1076.	2.2	4
850	Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy. Journal of Personalized Medicine, 2023, 13, 233.	2.5	1
851	Predictors of urinary function recovery after laparoscopic and robot-assisted radical prostatectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2023, 49, 50-60.	1.5	3
852	Decision Regret in Patients with Localised Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2023, 6, 456-466.	5.4	2
853	Patient-reported Satisfaction and Regret Following Focal Therapy for Prostate Cancer: A Prospective Multicenter Evaluation. European Urology Open Science, 2023, 50, 10-16.	0.4	0
854	Late Toxicities of Prostate Radiotherapy: Can We Further SMARTen Up the Therapeutic Index?. European Urology Focus, 2023, 9, 414-418.	3.1	1
855	The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam. European Urology Open Science, 2023, 51, 1-6.	0.4	0
856	GI factors, potential to predict prostate motion during radiotherapy; a scoping review. Clinical and Translational Radiation Oncology, 2023, 40, 100604.	1.7	0
857	Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. European Urology Open Science, 2023, 51, 89-94.	0.4	1
858	Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients. Radiotherapy and Oncology, 2023, 183, 109632.	0.6	1

#	Article	IF	CITATIONS
859	The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center. Advances in Radiation Oncology, 2023, 8, 101193.	1.2	0
860	Prostatakarzinom: kurative Therapie. Springer Reference Medizin, 2022, , 1-22.	0.0	0
861	Prevalence and Morbidity of Local Treatment-Related Side Effects in Metastatic Prostate Cancer Patients. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 204.e1-204.e6.	1.6	1
862	Encouraging Patients to Ask Questions: Development and Pilot Testing of a Question Prompt List for Patients Undergoing a Biopsy for Suspected Prostate Cancer. Current Oncology, 2023, 30, 2088-2104.	2.2	0
863	Men's Achilles' heel: prostate cancer and the reconstruction of masculinity. Culture, Health and Sexuality, 2023, 25, 1675-1689.	1.8	6
864	The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study. Cancers, 2023, 15, 1288.	3.7	4
865	Advanced hydrogels: New expectation for the repair of organic erectile dysfunction. Materials Today Bio, 2023, 19, 100588.	5.5	1
866	A Personalized Clinical Dynamic Prediction Model to Characterize Prognosis for Patients With Localized Prostate Cancer: Analysis of the CHHiP Phase 3 Trial. International Journal of Radiation Oncology Biology Physics, 2023, 116, 1055-1068.	0.8	0
867	Lowâ€risk prostate lesions: An evidence review to inform discussion on losing the "cancer―label. Prostate, 2023, 83, 498-515.	2.3	1
868	Factors impacting on sexual function among men on active surveillance for prostate cancer. Prostate, 2023, 83, 678-687.	2.3	1
869	Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost. International Journal of Radiation Oncology Biology Physics, 2023, 116, 1069-1078.	0.8	2
870	Localized Prostate Cancer — Then and Now. New England Journal of Medicine, 2023, 388, 1617-1618.	27.0	2
871	Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment. , 2023, 2, .		18
872	Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA). Nutrients, 2023, 15, 1369.	4.1	2
873	Recent Advances in Radiotherapy Modalities for Prostate Cancer. Acta Clinica Croatica, 2022, , .	0.2	0
874	Proton therapy for highâ€risk prostate cancer: Results from the Proton Collaborative Group PCG 001â€09 prospective registry trial. Prostate, 2023, 83, 850-856.	2.3	1
875	Current Knowledge on Radiation-Therapy-Induced Erectile Dysfunction in Prostate-Cancer Patients: A Narrative Review. Uro, 2023, 3, 104-116.	0.8	0
876	Active Surveillance for Prostate Cancer: Past, Current, and Future Trends. Journal of Personalized Medicine, 2023, 13, 629.	2.5	5

#	Article	IF	CITATIONS
877	Erectile Dysfunction in Pelvic Cancer Survivors and Current Management Options. Journal of Clinical Medicine, 2023, 12, 2697.	2.4	1
878	A modeling study to estimate prostate cancerâ€specific mortality on active surveillance for men with favorable intermediateâ€risk prostate cancer: Results from the <scp>SEARCH</scp> cohort. Cancer Medicine, 0, , .	2.8	1
879	Screening for Prostate Cancer. New England Journal of Medicine, 2023, 388, 1405-1414.	27.0	22
880	Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review. BMC Cancer, 2023, 23, .	2.6	1
881	Mental wellbeing and quality of life in prostate cancer (MIND-P): Protocol for a multi-institutional prospective cohort study. PLoS ONE, 2023, 18, e0284727.	2.5	0
882	Re: Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. European Urology, 2023, , .	1.9	0
883	Changes in male sexuality after urologic cancer: a narrative review. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2023, 49, 175-183.	1.5	6
884	Long-term follow-up suggests high satisfaction rates for bulbomembranous radiation-induced urethralÂstenoses treated with anastomotic urethroplasty. World Journal of Urology, 0, , .	2.2	0
885	Patient-reported outcomes after curative treatment for prostate cancer with prostatectomy, primary radiotherapy or salvage radiotherapy. Acta Oncológica, 2023, 62, 657-665.	1.8	0
886	Anterior Sphincter-sparing Suturing of the Vesicourethral Anastomosis During Robotic-assisted Laparoscopic Radical Prostatectomy. European Urology Open Science, 2023, 52, 109-114.	0.4	0
887	The lived experience of prostate cancer: 10-year survivor perspectives following contemporary treatment of localized prostate cancer. Journal of Cancer Survivorship, 0, , .	2.9	1
888	Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer. Nature Reviews Urology, 2023, 20, 332-355.	3.8	3
889	Deep learning for automated contouring of neurovascular structures on magnetic resonance imaging for prostate cancer patients. Physics and Imaging in Radiation Oncology, 2023, 26, 100453.	2.9	2
890	Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. European Urology, 2023, 84, 547-560.	1.9	1
891	Clinical characteristics analysis and prognostic nomogram for predicting survival in patients with second primary prostate cancer: a population study based on SEER database. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	0
892	Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials. Value in Health, 2023, , .	0.3	0
893	"Keep It Short and Simple― Perceptions of patients and healthcare professionals on the use of a mobile health app in the care for patients undergoing radical prostatectomy. BJUI Compass, 0, , .	1.3	0
894	Rehabilitation nach Radiotherapie des lokalisierten Prostatakarzinoms. Springer Reference Medizin, 2023, , 2707-2718.	0.0	0

#	Article	IF	CITATIONS
895	Prostatakarzinom: kurative Therapie. Springer Reference Medizin, 2023, , 1571-1592.	0.0	0
896	The Association Between Low Preoperative Serum Testosterone and Post-radical Prostatectomy Urinary Function. Urology, 2023, 180, 190-193.	1.0	0
897	Optimizing the question: Balancing significance and feasibility. , 2023, , 113-118.		0
898	Diagnostic discovery. , 2023, , 59-65.		0
899	Developing and validating utility parameters to establish patient-reported outcome-based perioperative symptom management in patients undergoing prostatectomy: a multicentre, prospective, observational cohort study protocol. BMJ Open, 2023, 13, e074763.	1.9	0
901	Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic Review. European Urology Oncology, 2023, , .	5.4	Ο
902	External beam radiotherapy of prostate cancer with or without high dose-rate brachytherapy: the Norwegian experience with long-term urinary and bowel adverse effects. Scandinavian Journal of Urology, 0, 58, 68-75.	1.0	0
903	Changes in Stress Reduction Following a 28-Day Prostate Cancer Patient Empowerment Program (PC-PEP) among Prostate Cancer Survivors. Current Oncology, 2023, 30, 7936-7949.	2.2	Ο
904	Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis. Journal of Medical Economics, 0, , 1-13.	2.1	0
905	The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer. Current Oncology, 2023, 30, 8092-8110.	2.2	Ο
906	Effects of surgery versus radiotherapy in patients with localized prostate cancer in terms of urinary, bowel, and sexual domains. Cancer Medicine, 2023, 12, 18176-18188.	2.8	1
907	Circulating Tumor Cells in Men Treated for Prostate Cancer. Current Cancer Research, 2023, , 565-574.	0.2	0
908	Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4Âweeks versus 2Âweeks (SHORTER). BMC Cancer, 2023, 23, .	2.6	2
910	Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547–58. European Urology, 2023, , .	1.9	5
911	Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management. Urologic Oncology: Seminars and Original Investigations, 2023, , .	1.6	0
912	From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life. European Urology Oncology, 2023, , .	5.4	1
913	Clinical and functional outcomes for riskâ€appropriate treatments for prostate cancer. BJUI Compass, 0, , .	1.3	1
914	Variations in predictors for urinary continence recovery at different time periods following robotâ€assisted radical prostatectomy. Asian Journal of Endoscopic Surgery, 2024, 17, .	0.9	0

#	Article	IF	CITATIONS
915	Impact of postoperative sexual function on health-related quality of life after robot-assisted radical prostatectomy. Current Urology, 0, , .	0.6	0
916	Real-World Complications of the SpaceOAR Hydrogel Spacer: A Review of the Manufacturer and User Facility Device Experience Database. Urology, 2023, , .	1.0	0
917	Radiological evaluation of an iodised hydrogel for prostate radiotherapy applications. Physica Medica, 2023, 114, 103155.	0.7	0
919	Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors. Acta Oncológica, 2023, 62, 1440-1450.	1.8	0
921	A pooled long-term follow-up after radiotherapy for prostate cancer with and without a rectal hydrogel spacer: impact of hydrogel on decline in sexual quality of life. Frontiers in Oncology, 0, 13, .	2.8	1
922	Sexual health problems of patients with cancer: A bibliometrics study and visualization analysis via CiteSpace. Heliyon, 2023, 9, e20856.	3.2	0
923	Reporting Real-World Data on Prostate Cancer Treatment Outcomes to Consumers: The Prostate Cancer Report Card. European Journal of Cancer Care, 2023, 2023, 1-12.	1.5	0
924	Quality of life after nonâ€nerveâ€sparing, robotâ€assisted radical prostatectomy. Asia-Pacific Journal of Clinical Oncology, 2024, 20, 93-100.	1.1	0
925	Protocol for a systematic review and meta-analysis on preoperative risk factors for failure after fixed sling implantation for post-prostatectomy stress urinary incontinence. F1000Research, 0, 12, 19.	1.6	0
926	Active Surveillance of Low-Risk Differentiated Thyroid Cancer. , 2023, , 37-53.		0
927	Pathway for post-prostatectomy urinary incontinence: impact on patient confidence and satisfaction. British Journal of Nursing, 2023, 32, S17-S23.	0.7	0
928	Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging–Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial. International Journal of Radiation Oncology Biology Physics. 2024. 118. 986-997.	0.8	1
929	Management of Patients With a Negative Multiparametric Prostate MRI Examination: <i>AJR</i>		
	Panel Narrative Review. American Journal of Roentgenology, 0, , .	2.2	1
930	Panel Narrative Review. American Journal of Roentgenology, 0, , . Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry. BMC Urology, 2023, 23, .	2.2	0
930 931	Patient-reported outcomes before treatment for localized prostate cancer: are there differences		
	Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry. BMC Urology, 2023, 23, . Comparative effectiveness of new treatment modalities for localized prostate cancer through	1.4	0
931	Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry. BMC Urology, 2023, 23, . Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures. Clinical and Translational Radiation Oncology, 2024, 44, 100694. Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery	1.4	0

		CITATION REPORT		
#	Article		IF	CITATIONS
935	Postâ \in prostatectomy incontinence: a guideline of guidelines. BJU International, O, , .		2.5	1
936	Review of Current Treatment Intensification Strategies for Prostate Cancer Patients. Car 5615.	ncers, 2023, 15,	3.7	0
937	Validation of Claims Data for Absorbing Pads as a Measure for Urinary Incontinence afte Prostatectomy, a National Cross-Sectional Analysis. Cancers, 2023, 15, 5740.	r Radical	3.7	0
938	Health-related quality of life among prostate cancer survivors with metastatic disease an non-metastatic disease and men without a cancer history in the USA. Journal of Cancer 90, , .	d Survivorship,	2.9	1
939	2023 Update On the Screening and Treatment of Localized Prostate Cancer. , 0, , 4-7.			0
940	Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Pr Cancer with Prostate-Specific Membrane Antigen–Targeted ¹⁸ F-DCFPyL I Nuclear Medicine, 2024, 65, 87-93.		5.0	0
941	Current Controversy and Developments Regarding the Cytoreductive Prostatectomy for Oligometastatic Prostate Cancer. Technology in Cancer Research and Treatment, 2023,		1.9	0
942	Is There a Difference in the Incidence of Depression between Radiation and Surgical Trea Patients with Prostate Cancer?. World Journal of Men?s Health, 2024, 42, 237.	tments in	3.3	0
943	Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated for localized prostate cancer: AÂpropensity score-matched analysis. Strahlentherapie Un 0, , .	arc therapy d Onkologie,	2.0	0
944	Novel nerve-sparing robot-assisted radical prostatectomy with endopelvic fascia preserve long-term outcomes for a single surgeon. Scientific Reports, 2024, 14, .	ation and	3.3	0
945	Patient-reported Side Effects 1 Year After Radical Prostatectomy or Radiotherapy for Pro A Register-based Nationwide Study. European Urology Oncology, 2024, , .	state Cancer:	5.4	0
946	Determinants of active surveillance uptake in a diverse populationâ€based cohort of me prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS). Cancer, 202	n with Iowâ€risk 4, 130, 1797-1806.	4.1	0
947	Functional Outcomes After Localized Prostate Cancer Treatment. JAMA - Journal of the A Medical Association, 2024, 331, 302.	merican	7.4	0
948	Quality of Life Longitudinal Evaluation in Prostate Cancer Patients from Radiotherapy St after IMRT-IGRT. Current Oncology, 2024, 31, 839-848.	art to 5 Years	2.2	0
949	Quantified treatment effect at the individual level is more indicative for personalized rad prostatectomy recommendation: implications for prostate cancer treatment using deep Journal of Cancer Research and Clinical Oncology, 2024, 150, .		2.5	0
950	Preferences for Tailored Support – Patients' and Health Care Professionals' Ex Symptoms and Self-Management Strategies During the First Year After Curatively Intenc Cancer Treatment. Patient Preference and Adherence, 0, Volume 18, 275-288.		1.8	0
951	Quality of Decision Making in Radiation Oncology. Clinical Oncology, 2024, , .		1.4	0
952	Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone m prostate cancer. Frontiers in Endocrinology, 0, 15, .	etastases of	3.5	0

\sim			D		
	ATI	$\cap N$		'DO	DT
	~ I I			.F U	IV I

#	Article	IF	CITATION
953	Leaking Bodies, Sexual Health, and Masculinity. , 2024, , 45-60.		0
954	Men and Their Health. , 2024, , 1-14.		0
955	Development of depression in patients using androgen deprivation therapy: A systemic review and metaâ€analysis. Prostate, 0, , .	2.3	0
956	Prostate cancer grading framework based on deep transfer learning and Aquila optimizer. Neural Computing and Applications, 2024, 36, 7877-7902.	5.6	0
957	Exploring Unmet Needs in Prostate Cancer Care: A Cross-sectional Descriptive Study. European Urology Open Science, 2024, 62, 36-42.	0.4	0
958	Focal brachytherapy as definitive treatment for localized prostate cancer: A systematic review and meta-analysis. Brachytherapy, 2024, , .	0.5	0
959	Comparison of sexual function after robot-assisted radical prostatectomy and carbon-ion radiotherapy for Japanese prostate cancer patients using propensity score matching. BMC Cancer, 2024, 24, .	2.6	0
960	Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	0
961	Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE― World Journal of Urology, 2024, 42, .	2.2	0
962	Demographic and Clinical Factors Associated With Health-Related Quality-of-Life Profiles Among Prostate Cancer Survivors. JCO Oncology Practice, 0, , .	2.9	0